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HIV	Pathogenesis	HIV	 essentially	 targets	 cells	 of	 the	 immune	 system	 eventually	 causing	 a	profound	defect	in	immune	function	that	leaves	the	infected	person	vulnerable	to	a	number	of	 infections	 that	would	normally	not	 cause	disease.	 	 This	 severe	 state	 of	immune	insufficiency	is	called	acquired	immunodeficiency	syndrome	or	AIDS.		The	virus	is	most	often	transmitted	sexually,	but	can	also	have	parenteral	or	mother-to-	infant	 transmission	 (Knipe	 and	 Howley,	 2013).	 	 Using	 simian	 immunodeficiency	virus	(SIV)	models,	it	has	been	shown	that	CD4+	T	cells	are	the	first	cell	types	to	be	
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infected	 during	 transmission	 across	mucosal	 barriers	 and	 there	 is	 a	 limited	 time	period	 in	 which	 the	 immune	 response	 or	 anti-retroviral	 drugs	 can	 block	 further	spread	of	the	virus	in	the	host	(Haase,	2011).		Viral	tropism,	or	the	ability	to	infect	specific	cell	types,	is	determined	by	the	presence	of	CD4	and	either	CCR5	or	CXCR4,	and	so	the	major	targets	of	infection	in	vivo	are	CD4+	T	cells	and	macrophages.	After	 transmission	 of	 the	 virus	 to	 an	 uninfected	 person,	 there	 are	 usually	three	stages	of	 infection:	acute	 infection,	chronic	 infection,	and	AIDS	(Figure	1-3).		Acute	 or	 primary	 HIV	 infection	 is	 typically	 characterized	 by	 high	 rates	 of	 HIV	replication	with	the	median	plasma	viral	level	around	106	or	107	genome	copies/mL	at	 the	 peak	 of	 infection	 (Knipe	 and	 Howley,	 2013).	 	 This	 massive	 infection	 is	accompanied	 by	 a	 significant	 loss	 of	 CD4+	 T	 cells.	 	 After	 about	 6	 to	 12	 months,	viremia	will	drop	to	a	mean	set	point	of	30,000	copies/mL,	where	it	will	very	slowly	increase	 over	 the	 course	 of	 chronic	 infection,	 characterized	 by	 a	 clinical	 latency	period.		This	period	of	chronic	infection	can	range	from	6	months	to	over	20	years,	and	is	usually	asymptomatic	with	a	gradual	CD4+	T	cell	decline	until	the	individual	reaches	very	low	levels	of	CD4+	T	cells.		A	patient	with	a	severe	immune	depletion,	defined	 by	 a	 CD4	 cell	 count	 of	 less	 than	 200	 cells/uL	 or	 the	 onset	 of	 specific	opportunistic	infections	or	cancers,	now	has	AIDS	(Knipe	and	Howley,	2013).	Currently,	therapies	prevent	disease	progression	by	inhibiting	viral	enzymes,	including	 reverse	 transcriptase,	 integrase,	 and	protease	 or	 by	blocking	 viral	 entry	into	 a	 cell.	 	 When	 used	 in	 combinations	 for	 optimal	 treatment,	 referred	 to	 as	combination	antiretroviral	therapy	(cART),	these	highly	potent	drugs	reduce	plasma	viral	 loads	 to	 levels	 below	detection	 by	 the	 commonly-used	 clinical	 assays	with	 a	
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limit	of	detection	of	50	copies/mL	or	less	(Maldarelli	et	al.,	2007).		However,	single	copy	 assays	 still	 detect	 viral	 genomes	 in	 plasma	 samples	 after	 7	 to	 12	 years	 of	optimal	treatment	in	HIV-infected	people	(Palmer	et	al.,	2008;	Riddler	et	al.,	2016).		In	longitudinal	sampling	of	64	HIV+	individuals	on	cART	after	4	to	12	years	of	viral	suppression,	 it	was	 shown	 that	 residual	 virus	 continues	 to	 decline	 at	 a	 very	 slow	rate	 (Riddler	 et	 al.,	 2016).	 	 Even	 with	 optimal	 viral	 suppression,	 patients	 on	treatment	may	 occasionally	 have	 blips	 of	 viremia,	where	 plasma	 virus	 transiently	increases	to	levels	that	are	detectable	by	clinical	assays	(Knipe	and	Howley,	2013).	Thus,	despite	years	of	viral	suppression,	disruption	of	treatment	inevitably	leads	to	a	rebound	in	circulating	virus.		
HIV	Genetic	Diversity	and	Tropism	HIV-1	 isolates	 from	 infected	 persons	 around	 the	 world	 exhibit	 a	 large	amount	 of	 genetic	 heterogeneity,	 resulting	 in	 multiple	 clades	 of	 HIV	 and	recombinant	strains.	Clade	C	virus	is	the	most	prevalent,	commonly	found	in	areas	of	Africa	and	India,	and	now	accounts	for	almost	half	of	all	HIV	infections	(Freed	and	Martin,	2013).	The	best-studied	subtype	 is	clade	B	virus,	 found	most	commonly	 in	the	 United	 States,	 Western	 Europe,	 and	 Australia.	 	 Even	 within	 an	 infected	individual,	 HIV	 exists	 as	 a	 quasispecies,	 a	 genetically	 diverse	 and	 evolving	population,	with	an	estimated	increase	in	genetic	diversity	of	1%	per	year	from	the	initial	 founder	 viral	 strain	 during	 acute	 infection	 (Freed	 and	Martin,	 2013).	 	 The	high	 genetic	 diversity	 of	HIV	 populations	 are	 due	 to	multiple	 reasons.	 	 There	 are	many	infected	individuals	globally,	and	in	each	of	these	individuals,	in	the	absence	of	
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Resting	CD4+	T	Cells	It	is	well	established	that	resting	memory	CD4+	T	cells	are	a	stable	reservoir	of	 latent	HIV	 infection	(Finzi	et	al.,	1999;	Siliciano	et	al.,	2003)	 (Figure	1-4).	 	One	study	 that	 estimated	 the	 size	of	 the	T	 cell	 reservoir	using	a	viral	outgrowth	assay	found	 that	 the	CD4+	T	cell	 reservoir	decays	extremely	slowly	with	a	half-life	of	44	months	 (Siliciano	 et	 al.,	 2003).	 	 Another	 study	 examining	 resting	memory	 T	 cells	predicted	no	significant	loss	of	integrated	HIV	DNA	over	time,	with	a	predicted	half-life	of	roughly	25	years	(Murray	et	al.,	2014).		A	recent	study	of	one	patient	found	a	unique	integration	site	for	a	fully	replication-competent	and	infectious	HIV	genome	that	 was	 clonally	 expanded	 in	 peripheral	 blood	 mononuclear	 cells	 (PBMCs)	(Simonetti	 et	 al.,	 2016),	 although	 whether	 functional	 virus	 can	 persist	 via	 clonal	
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expansion	 of	 CD4+	 T	 cells	 in	 the	 majority	 of	 patients	 with	 long-term	 viral	suppression	remains	to	be	known.	Resting	CD4+	T	cells	contain	barriers	to	productive	viral	 infection,	 including	rigid	 cortical	 actin,	 which	 inhibits	 transport	 of	 the	 preintegration	 complex,	expression	of	cellular	restriction	 factors	 that	 inhibit	 reverse	transcription	and	 low	transcriptional	activation	(Pan	et	al.,	2013).	Because	of	these	barriers	to	infection	of	resting	 T	 cells,	 most	 latent	 infection	 may	 occur	 when	 infected,	 activated	 T	 cells	become	 quiescent.	 	 Alternatively,	 direct	 latent	 infection	 of	 resting	 T	 cells	may	 be	facilitated	 by	 cytokines,	 endothelial	 cells,	 or	 other	 environmental	 interactions	((Shen	et	al.,	2013),	reviewed	in	(Pace	et	al.,	2011)).			The	gold	standard	for	the	detection	of	latently	infected	cells	utilizes	an	assay	in	 which	 resting	 memory	 CD4+	 T	 cells	 are	 activated	 and	 viral	 outgrowth	 is	measured.	 	 However,	 a	 recent	 study	 indicates	 that	 this	 technique	 potentially	underestimates	latent	genomes	in	circulating	resting	T	cells	by	up	to	60-fold	(Ho	et	al.,	 2013).	 	 In	 this	 study,	 Ho	 et	 al	 found	 a	 significant	 subset	 of	 the	 non-induced	proviruses	 did	 not	 contain	 lethal	 mutations	 indicating	 that	 these	 non-induced	proviruses	 are	 capable	 of	 producing	 new	 infectious	 virions	 upon	 reactivation.		Additionally,	 reconstructed	 non-induced	 proviruses	 produced	 virions	with	 similar	infectivity	to	those	reconstructed	from	induced	proviruses.	 	Because	these	proviral	genomes	did	 not	 appear	 to	 be	 activated	 and	 cleared	by	 standard	T	 cell	 activation	methods,	 there	 appear	 to	 be	 barriers	 to	 reactivation	 of	 functional	 proviruses	 in	latently	infected	resting	T	cells	that	are	not	well	understood	(Ho	et	al.,	2013).	
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Resting	memory	T	cells	have	been	divided	into	different	subtypes,	including	central	memory	 (TCM),	 transitional	memory	 (TTM),	 effector	memory	 (TEM),	 and	 the	recently-characterized	stem	cell	memory	T	cells	(TSCM).	 	TCM	cells	localize	to	lymph	nodes	 and,	 upon	 stimulation,	will	 become	 TEM	 cells	 that	 can	move	 into	 tissues	 to	perform	inflammatory	and	cytotoxic	functions	(Sallusto	et	al.,	1999).			TTM	cells	show	an	 intermediate	 phenotype	 between	 TCM	 and	 TEM	 cells	 (Riou	 et	 al.,	 2007).	 	 The	contribution	of	each	of	these	subtypes	to	the	HIV-1	reservoir	 is	variable	(Buzon	et	al.,	2014;	Chomont	et	al.,	2009;	Gattinoni	et	al.,	2011;	Riou	et	al.,	2007;	Sallusto	et	al.,	1999).	 	 A	 study	 by	 Chomont	 et	 al.	 implicated	 TCM	 and	 TTM	 cells	 as	 the	 major	components	 of	 the	CD4+	T	 cell	 reservoir	 (Chomont	 et	 al.,	 2009).	 	 TCM	 cells	 form	a	reservoir	 of	 reduced	 size	 that	 decays	 slowly	 in	 HIV-infected	 people	 with	 normal	CD4+	 T	 cell	 counts	 who	 started	 treatment	 early	 after	 infection.	 	 TTM	 cells,	 on	 the	other	hand,	are	the	primary	reservoir	in	HIV-infected	people	with	lower	CD4	counts	at	the	time	of	cART	initiation.	 	Evidence	was	presented	that	these	latently	infected	cells	may	be	maintained	over	time	by	homeostatic	proliferation	due	to	continuous	immune	activation	(Chomont	et	al.,	2009).				TSCM	cells	are	the	least	differentiated	T	cell	subset	with	the	greatest	capacity	for	self-renewal	(Gattinoni	et	al.,	2011).		Recently,	it	was	reported	that	TSCM	cells	are	also	 infected	by	HIV	 (Buzon	 et	 al.,	 2014;	 Flynn	 et	 al.,	 2014;	Gattinoni	 et	 al.,	 2011;	Tabler	et	al.,	2014).		Buzon	et	al.	studied	these	long-lived	cells	in	HIV-infected	people	with	 optimal	 viral	 suppression	 for	 a	 median	 of	 7	 years	 and	 found	 that	 latently	infected	CD4+	TSCM	 cells	 contribute	a	 significant	portion	of	 the	HIV	DNA	 in	 resting	memory	T	cells.		The	TSCM	contribution	increased	over	the	course	of	therapy	as	more	
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differentiated	T	cell	subsets	that	initially	contributed	to	the	reservoir	were	lost.		The	authors	provided	a	 longitudinal	phylogenetic	analysis	of	plasma	and	resting	T	cell	viral	 sequences	 in	3	HIV-infected	people,	beginning	pre-therapy	and	continuing	at	multiple	 time	 points	 up	 to	 13	 years	 post-diagnosis.	 	 These	 data	 provide	 evidence	that	TSCM	 cells	may	be	 infected	early	 and	 continue	 to	harbor	viral	 genomes	 for	 an	extended	period	(Buzon	et	al.,	2014).		Thus,	eradication	strategies	should	also	target	TSCM	cells.	Though	 it	 is	 widely	 accepted	 that	 resting	 CD4+	 T	 cells	 are	 an	 important	source	of	latent	infection,	it	is	not	clear	that	this	is	the	only	reservoir	contributing	to	HIV	persistence.		One	study	of	two	optimally	treated	HIV-infected	people	found	that	sub-genomic	amplicons	derived	 from	plasma	virus	exactly	matched	 the	same	sub-genomic	amplicons	derived	from	virus	produced	by	reactivated	resting	CD4+	T	cells	(Anderson	et	al.,	2011).		However,	other	studies	that	have	isolated	residual	plasma	virus	 from	optimally	 treated	 people	with	 suppressed	 viral	 loads	were	 not	 able	 to	match	viral	 genome	sequences	 to	any	provirus	 found	 in	 circulating	 resting	T	 cells	(Bailey	et	al.,	2006;	Brennan	et	al.,	2009;	Sahu	et	al.,	2009).		The	study	by	Brennan	et	

















HIV	Infection	of	HSPCs	A	long-lived	infected	HSPC	could	also	be	an	important	contributor	to	residual	HIV	 in	 treated	 HIV-infected	 people	 as	 subsets	 of	 CD34+	 HSPCs	 do	 express	 HIV	receptors	 (Carter	et	al.,	2011;	Carter	et	al.,	2010).	 	Several	 studies	 looking	at	both	mRNA	and	protein	levels	have	shown	that	a	portion	of	CD34+	cells	will	express	CD4,	though	 expression	 levels	 are	 noted	 to	 be	 less	 than	 in	monocytes	 or	 CD4+	 T	 cells	(Louache	et	al.,	1994;	Muench	et	al.,	1997;	Zauli	et	al.,	1994).	 	CD34+	cells	vary	 in	their	expression	of	CCR5	and	CXCR4,	and	more	primitive	cells	within	this	population	tend	to	express	CXCR4	and	not	CCR5	(Carter	et	al.,	2011;	Carter	et	al.,	2010;	Ishii	et	al.,	 1999;	 Nixon	 et	 al.,	 2013;	 Ruiz	 et	 al.,	 1998;	 Shen	 et	 al.,	 1999).	 According	 to	another	study,	CXCR4	expression	occurs	earlier	than	other	lymphoid	markers,	IL-7	receptor	 and	 terminal	 deoxynucleotidyl	 transferase	 (TdT),	 on	 CD34+	 progenitors,	and	is	suggested	to	indicate	a	more	restricted	lymphoid	potential	(Ishii	et	al.,	1999).		The	 expression	 of	 CD4	 with	 either	 co-receptor	 does	 suggest	 that	 HPCs	 can	 be	infected	by	HIV-1.	Over	20	years	ago,	the	hematopoietic	progenitor	compartment	in	bone	marrow	was	first	investigated	and	it	was	shown	that	rare	infection	of	CD34+	cells	could	occur	both	in	vitro	and	in	vivo	(Davis	et	al.,	1991;	Folks	et	al.,	1988;	Neal	et	al.,	
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1995;	Stanley	et	al.,	1992).		However,	given	the	available	technologies,	the	researchers	conducting	these	studies	could	not	exclude	contamination	from	other	cell	types	(Chelucci	et	al.,	1995;	Shen	et	al.,	1999;	Weichold	et	al.,	1998).		Because	some	analyses	of	plasma	virus	found	that	certain	identical	sequences	predominate	in	circulation	over	multiple	time	points,	it	was	proposed	that	latently-infected	stem	cells,	with	the	capacity	for	self-renewal,	contributed	clonal	virus	upon	intermittent	activation	(Palmer	et	al.,	2008).		Indeed,	a	number	of	studies	have	provided	evidence	that	HIV	can	infect	CD34+	bone	marrow	progenitors	(Bordoni	et	al.,	2015;	Carter	et	al.,	2011;	Carter	et	al.,	2010;	McNamara	et	al.,	2012;	McNamara	et	al.,	2013;	Nixon	et	al.,	2013;	Redd	et	al.,	2007).		A	study	of	HIV-infected	people	in	Africa	revealed	that	HIV-1	subtype	C	could	infect	HSPCs	in	vitro	and	in	vivo.		Participants	with	HIV-infected	bone	marrow	progenitors	also	had	higher	rates	of	anemia	(Redd	et	al.,	2007).	More	recent	studies	have	now	shown	that	HIV-1	subtypes	B,	C,	and	D	can	all	infect	HSPCs	in	vitro	(Carter	et	al.,	2010).			Additionally,	 these	studies	demonstrate	 that	HIVs	 that	use	CXCR4	 for	entry	can	infect	multipotent	progenitors	that	form	colonies	of	multiple	different	lineages	in	methylcellulose	assays	(Carter	et	al.,	2011).	 	Notably,	CXCR4-tropic	HIV	can	also	infect	 bona	 fide	 stems	 cells	 in	 vitro	 based	 on	 engraftment	 and	 production	 of	 all	major	 hematopoietic	 lineages	 in	 an	 irradiated	 immune-deficient	mouse	 (Carter	 et	al.,	2011;	Carter	et	al.,	2010).	 	However,	CCR5-tropic	virus	seemed	unable	to	infect	multipotent	progenitors,	perhaps	due	to	the	low	or	absent	CCR5	expression	in	these	most	immature	subsets	(Carter	et	al.,	2011).		In	addition	to	entry	restrictions	due	to	limited	receptor	expression,	an	analysis	of	post-entry	infection	of	CD34+	cord	blood	
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progenitors	suggested	that	viral	DNA	synthesis	and	nuclear	entry	may	be	restricted	in	HSPCs	resulting	in	the	low	infection	rates	seen	in	these	cell	types	(Griffin	and	Goff,	2015).	To	 study	 latent	 infection	 in	 HSPCs,	 Carter	 et	al.	 utilized	 an	 HIV	 molecular	clone	that	expresses	viral	proteins	under	the	control	of	the	viral	promoter	and	GFP	under	a	constitutively-active	promoter	(Carter	et	al.,	2010).		Thus,	it	was	possible	to	distinguish	uninfected	(GFP-Gag-),	actively	infected	(GFP+Gag+)	and	latently	infected	(GFP+Gag-)	 cells.	 	When	 latently	 infected	 HSPCs	were	 treated	with	 cytokines	 that	stimulate	 myeloid	 lineage	 differentiation	 (granulocyte	 macrophage-colony	stimulating	 factor	 [GM-CSF]	 and	 tumor	 necrosis	 factor	 [TNF]-α),	 viral	 gene	expression	was	induced.		These	studies	demonstrate	that	HIV	can	infect	HSPCs	and	cause	both	active	and	latent	infection	in	vitro.	In	 addition,	 HIV	 Gag+	 CD34+	 progenitors	 were	 detected	 in	 bone	 marrow	aspirates	 from	 some	 HIV+	 donors	 with	 high	 viral	 loads	 (Carter	 et	 al.,	 2010).		Progenitor	 cells	 from	 one	 donor	 that	 initially	 lacked	 detectable	 Gag	 expression,	expressed	Gag	upon	culture	with	GM-CSF	and	TNF-α.	Examination	of	HIV-infected	individuals	 on	 cART	 with	 undetectable	 viral	 loads	 revealed	 no	 detectable	 Gag	expression	in	HSPCs,	but	HIV	genomes	were	amplified	with	quantitative	PCR	from	4	out	 of	 9	 donors	 (Carter	 et	 al.,	 2010).	 	 These	 initial	 studies	 provided	 evidence	supporting	the	conclusion	that	latent	HIV	infection	occurs	in	bone	marrow	HSPCs	in	
vivo.	 Two	 other	 groups	 have	 searched	 for	 latent	 HIV	 genomes	 in	 CD34+	 bone	marrow	cells	from	HIV+	donors	on	long-term	cART	without	success.		Josefsson	et	al.	
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did	 not	 detect	 HIV	 amplicons	 in	 CD4-	 CD34+	 HSPCs	 in	 a	 cohort	 of	 eight	 virally	suppressed	 HIV-infected	 people:	 five	 who	 initiated	 cART	 during	 acute	 or	 early	infection	 and	 three	 who	 started	 cART	 during	 chronic	 infection	 (Josefsson	 et	 al.,	2012).	 	 In	 this	 study,	 the	 authors	 removed	 CD4+	 cells	 to	 deplete	 the	 sample	 of	 T	lymphocytes.	However,	a	subset	of	HSPCs	express	CD4	and	CD4	is	required	for	HIV	infection	of	HSPCs	(Carter	et	al.,	2011).		Thus,	it	is	possible	that	the	negative	results	from	 this	 study	were	 due	 to	 the	 absence	 of	 susceptible	 cells	 in	 the	 samples.	 	 The	study	 by	 Durand	 et	al.	 tested	 HSPCs	 from	 a	 cohort	 of	 11	 optimally	 treated	 HIV-infected	people,	 10	 of	whom	were	diagnosed	prior	 to	 2001	 (Durand	 et	 al.,	 2012).		These	 investigators	were	 unable	 to	 detect	 HIV	DNA	 in	 CD34+	HSPCs	 by	 real-time	PCR.	 	 Nor	 could	 they	 detect	 virus	 produced	 using	 a	 co-culture	 assay	 of	 HSPCs	stimulated	with	GM-CSF	and	TNF-α	plus	activated	CD4+	lymphoblasts.		Based	on	the	latter	 study,	 some	 investigators	 suggested	 the	 possibility	 that	 CD4+	 T	 cell	contamination	confounded	prior	results	(Carter	et	al.,	2010).		However,	because	the	Durand	et	al.	study	was	not	powered	to	detect	DNA	in	HSPCs	from	donors	diagnosed	after	2001,	an	alternative	explanation	 is	 that	 it	 is	harder	to	detect	HIV	infection	of	HSPCs	 in	 people	 infected	 decades	 ago,	 before	 optimal	 therapy	 was	 available.		Indeed,	 all	 donors	 who	 tested	 positive	 in	 the	 prior	 study	 were	 diagnosed	 more	recently	(Carter	et	al.,	2010).			
	
Targeting	HIV	Reservoirs	As	discussed	above,	latently	infected	cells	do	not	produce	viral	proteins	that	would	 lead	 to	 cytopathic	 effects	 and	 eventual	 cell	 death.	 	 	 In	 addition,	 latently	
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infected	cells	are	not	recognized	and	cleared	by	the	immune	system.		Current	anti-retroviral	drugs,	which	target	early	stages	of	the	HIV	replication	cycle,	cannot	inhibit	this	 non-productive	 infection	 once	 established.	 	 Thus,	 to	 eradicate	 these	 infected	cells,	 new	 latency-reversing	 agents	 (LRAs)	 are	 being	 developed	 to	 oppose	 latency	and	 thus	 force	 the	 virus	 to	 reveal	 itself.	 	 With	 concurrent	 cART,	 this	 approach,	termed	‘shock	and	kill,’	aims	to	eliminate	the	infected	reservoir	while	blocking	new	infection	events	(Deeks	et	al.,	2012).		Multiple	factors	contribute	to	latent	HIV	infection,	including	host	transcription	factors	that	bind	the	viral	promoter	and	epigenetic	changes	that	affect	chromatin	and	alter	accessibility	of	the	viral	promoter	to	transcriptional	machinery	(reviewed	in	(Trono	et	al.,	2010),	(Siliciano	and	Greene,	2011),	and	(Van	der	Sluis	et	al.,	2013)).		Thus,	current	work	has	focused	on	strategies	to	counteract	these	factors	in	favor	of	‘shock’	or	reactivation	of	latent	HIV.		Reactivated	infected	cells	then	need	to	be	‘killed,’	preferably	by	activation	of	cellular	death	pathways	or	through	the	host	immune	response.		A	few	of	the	major	strategies	for	reversing	HIV	latency	in	cell	lines	and	primary	T	cells	include	altering	chromatin	structure	with	histone	deacetylase	inhibitors	(HDACis),	increasing	availability	of	host	transcription	factors	with	the	use	of	protein	kinase	C/AKT	activators	like	disulfiram,	for	example,	and	stimulating	cells	with	immune-modulating	agents	such	as	IL-7	and	toll-like	receptor	agonists	(reviewed	extensively	in	(Remoli	et	al.,	2012;	Sgarbanti	and	Battistini,	2013;	Shirakawa	et	al.,	2013;	Xing	and	Siliciano,	2013)).		Our	laboratory	has	investigated	the	mechanism	of	latency	in	HSPCs	and	the	effect	of	different	LRAs	on	latent	infection	in	these	cells	(McNamara	et	al.,	2012).		In	this	study,	a	primary	cell	
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model	of	HIV	latency	in	HSPCs	indicated	that	latency	could	be	reversed	by	TNF-α	through	recruitment	of	NF-κB	in	these	cells.	Although	 many	 LRAs	 show	 potential	 for	 antagonizing	 HIV	 latency,	 recent	studies	 emphasize	 the	 need	 for	 further	 work	 to	 understand	 their	 clinical	 utility;	there	have	been	variable	results	when	the	same	compound	is	tested	side-by-side	in	different	 in	vitro	 latency	models	 and	 limited	 success	 thus	 far	 as	 sole	 therapies	 in	clinical	trials.		Spina	et	al.	(Spina	et	al.,	2013)	measured	the	effect	of	a	panel	of	LRAs	on	multiple	widely	used	models	of	latency	compared	with	the	standard	quantitative	viral	 outgrowth	 assay	 (QVOA)	 that	 uses	 patient-derived	 latently	 infected	 resting	CD4+	 T	 cells.	 	 They	 found	 that	 no	 in	vitro	 latency	model	 recapitulates	 the	 ex	vivo	QVOA	 results,	with	many	of	 the	models	 seemingly	biased	 towards	 reactivation	by	only	 specific	 classes	 of	 agents.	 	 PKC	 agonists	 generally	 induced	 latent	 HIV	 in	 the	majority	of	models	tested.		This	paper	underlines	the	potential	difficulties	of	using	a	single	in	vitro	model	to	identify	the	best	clinical	approach	for	‘shocking’	latent	HIV.			HDACis	(SAHA,	romidepsin	and	panobinostat)	and	disulfiram	did	not	induce	viral	 outgrowth	 in	 a	 newly	developed	ex	vivo	 assay	 that	may	better	 reflect	 in	vivo	conditions	 because	 it	 uses	 cells	 from	 HIV-infected	 people	 and	 does	 not	 employ	allogeneic	T	cells,	which	may	confound	results	(Bullen	et	al.,	2014).		Using	this	assay,	viral	 outgrowth	 was	 only	 observed	 from	 donor	 CD4+	 T	 cells	 treated	 with	 T	 cell	activating	 agents	 (Bullen	 et	 al.,	 2014).	 	 T	 cell	 activation	 and	 bryostatin-1,	 a	 PKC	agonist,	 significantly	 induced	 HIV	 mRNA	 expression	 whereas	 the	 HDACis	 and	disulfiram	did	not.		
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Methods	 that	 have	 demonstrated	 in	 vitro	 efficacy	 at	 reactivation	 of	 latent	CD4+	 T	 cell	 infection	 have	 been	 employed	 in	 clinical	 trials	 with	 limited	 success	(reviewed	 in	 (Rasmussen	et	 al.,	 2013)).	 	 	Thus,	more	 research	 is	needed	 to	better	understand	 this	 approach.	 	 Based	 on	 initially	 promising	 in	 vitro	 studies,	 SAHA,	panobinostat,	disulfiram,	and	IL-7	have	been	or	are	currently	being	tested	in	clinical	trials	with	no	clear	success	as	yet	(reviewed	in	(Rasmussen	et	al.,	2013)).		The	first	study	using	the	‘shock’	strategy	examined	the	effect	of	the	HDACi	valproic	acid	plus	a	 viral	 entry	 inhibitor	 over	 a	 three-month	 period	 (Lehrman	 et	 al.,	 2005).	 	 In	 this	study,	 four	HIV-infected	 individuals	 on	 cART	 had	 declines	 in	 numbers	 of	 infected	CD4+	T	cells	ranging	from	68%	to	over	84%.		However,	subsequent	trials	of	valproic	acid	 failed	 to	replicate	 these	results	 (Archin	et	al.,	2010;	Routy	et	al.,	2012;	Sagot-Lerolle	et	al.,	2008;	Siliciano	et	al.,	2007).			In	a	separate	study,	SAHA	treatment	was	found	to	increase	HIV	RNA	expression	in	resting	CD4+	T	cells,	but	had	no	detectable	impact	on	residual	plasma	viremia	(Archin	et	al.,	2012).		As	mentioned	above,	a	pilot	study	 of	 disulfiram	 treatment	 also	 demonstrated	 no	 effect	 on	 the	 size	 of	 the	circulating	 latent	 reservoir	 (Spivak	 et	 al.,	 2014).	 	 While	 clinical	 trials	 with	 single	agents	have	not	 yet	been	 successful,	 combinations	of	 LRAs	may	prove	effective	 in	further	studies	(Darcis	et	al.,	2015;	Xing	and	Siliciano,	2013).		
	
Clearing	Infection	after	Reversal	of	Latency	
	 Reactivating	reservoirs	of	 latent	HIV	 is	only	 the	 first	 step	of	 the	 ‘shock	and	kill’	approach.	 	Strategies	 to	eliminate	cells	after	reversal	of	 latency	are	an	equally	important	consideration	 for	a	cure.	 	The	two	main	strategies	 for	killing	a	cell	with	
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reactivated	 infection	 are	 activation	 of	 cell-death	 pathways	 and	 immune-mediated	clearance.	 	 In	 response	 to	viral	 infection,	 cell	death	pathways	become	activated	 to	prevent	 further	 spread	 of	 an	 infection	 (Lamkanfi	 and	Dixit,	 2010).	 	However,	HIV	encodes	strategies	to	delay	death	of	the	cell	and	favor	the	establishment	of	infection	(Badley	et	al.,	2013).	 	Further	research	should	consider	how	well	LRAs	of	 interest	can	induce	cell	death	in	the	various	cell	types	implicated	as	reservoirs	for	latent	HIV,	as	this	effect	may	be	cell-type	dependent.		One	study	found	that	ex	vivo	reactivation	of	 latent	 virus	with	 a	 6-day	 treatment	 of	 the	 HDACi	 SAHA	 in	 PBMCs	 from	 cART-treated	HIV-infected	people	did	not	reduce	the	number	of	latently-infected	cells	by	a	limiting	dilution	viral	outgrowth	assay	(Shan	et	al.,	2012).		Moreover,	SAHA	did	not	promote	cell	death	of	resting	CD4+	T	cells	in	an	in	vitro	latency	model,	whereas	T	cell	activation	did	(Shan	et	al.,	2012).	Another	strategy	for	clearing	latent	infection	utilizes	immune	defenses	to	target	and	kill	reactivated	cells.		According	to	the	common	definition	of	latency,	there	is	little	to	no	production	of	viral	proteins,	which	makes	them	poor	targets	for	cytotoxic	T	lymphocytes	(CTLs).		Anti-HIV	CTLs	limit	replication	of	the	virus,	but	these	cells	often	show	functional	defects	in	the	context	of	HIV	infection	(Migueles	et	al.,	2009).		A	small	group	of	HIV-infected	people,	referred	to	as	elite	controllers,	have	low	levels	of	HIV	replication	without	therapy,	and	these	HIV-infected	people	have	HIV-specific	CTLs	that	can	kill	autologous	resting	CD4+	T	cells	that	reactivate	latent	infection	ex	vivo	(Shan	et	al.,	2012).		In	cART-treated	HIV-infected	people,	latently-infected	resting	CD4+	T	cells	reactivated	with	SAHA	ex	vivo	are	not	cleared	by	CTLs	isolated	from	the	same	patient,	unless	those	CTLs	are	pre-stimulated	with	HIV	Gag	
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peptides	(Shan	et	al.,	2012).		The	susceptibility	of	infected	bone	marrow	HSPCs	to	immune	clearance	has	not	yet	been	assessed,	but	is	certainly	an	important	consideration	for	targeting	this	potential	reservoir.		
HIV	Cure	In	discussion	of	 a	 cure,	 two	 categories	have	been	proposed:	 sterilizing	 and	functional	(Dieffenbach	and	Fauci,	2011).		With	a	sterilizing	cure,	there	is	complete	eradication	of	all	replication-competent	HIV	from	a	patient.	On	the	other	hand,	with	a	functional	cure,	there	is	suppression	of	viral	replication	and	maintenance	of	CD4+	T	cell	function	without	anti-retroviral	therapy	indefinitely.	The	 only	 confirmed	 case	 of	 a	 sterilizing	 HIV	 cure	 occurred	 with	 a	 bone	marrow	transplant	for	acute	myeloid	leukemia	(Hutter	et	al.,	2009).		Often	referred	to	as	 the	Berlin	patient,	 this	40-year-old	man	received	an	allogeneic	bone	marrow	transplant	(BMT)	from	a	donor	with	a	homozygous	deletion	in	the	CCR5	gene.		Thus,	the	 donor	 cells	 were	 inherently	 resistant	 to	 HIV	 infection	 because	 they	 lacked	expression	of	an	HIV	co-receptor.		At	the	time	of	the	transplant,	the	patient	stopped	anti-retroviral	 therapy,	 and	 had	 no	 detectable	 viremia	 without	 antiretroviral	therapy	 for	over	5	years	 (Allers	et	 al.,	 2011;	Hutter	et	 al.,	 2009).	 	Additionally,	no	HIV	RNA	or	DNA	was	detectable	in	peripheral	blood,	bone	marrow	or	rectal	biopsies	(Allers	 et	 al.,	 2011).	 	Whether	 the	 donor	 stem	 cells	 or	 the	 bone	marrow	 ablation	strategy,	or	a	combination	of	the	two,	led	to	this	cure	is	unknown.	Thus	far,	there	have	been	a	few	instances	of	functional	cures	when	treatment	was	initiated	early	after	initial	infection.		In	one	case,	an	HIV-infected	woman	from	
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Mississippi	who	did	not	 receive	pre-natal	HIV	 treatment	gave	birth	 to	a	baby	 that	immediately	 received	 cART	 (Persaud	 et	 al.,	 2013).	 	 The	 infant’s	 initial	 viral	 load	decayed	after	 treatment	began,	 and,	 after	 treatment	was	 stopped	at	18	months	of	age,	circulating	virus	remained	undetectable	for	about	2	years	without	any	therapy.		Eventually	however,	the	child	developed	detectable	viremia	and	needed	to	resume	treatment	 (Martin	 and	 Siliciano,	 2016;	 NIAID,	 2014).	 	 The	 extended	 period	 of	virological	 control	 that	 occurred	 after	 therapy	 cessation	 offers	 hope	 that	 proviral	reservoirs	can	be	reduced	with	early	treatment.		A	complementary	study	of	infants	infected	perinatally	found	lower	levels	and	higher	decay	rates	of	PBMC	provirus	in	four	children	that	began	cART	sooner	(age	0.5-2.6	years)	compared	with	 four	that	began	cART	later	(age	6-14.7	years)	(Luzuriaga	et	al.,	2014).			In	 adults,	 recent	 studies	 suggest	 that	 early	 treatment	 can	 lead	 to	 a	 higher	than	 expected	 rate	 of	 post	 treatment	 controllers	 (PTCs).	 	 PTCs	 refer	 to	 treated	individuals	 who	 are	 found	 to	 have	 very	 low	 levels	 of	 viral	 replication	 after	interrupting	therapy.	 	A	group	of	14	adult	PTCs	were	identified	from	a	cohort	that	started	 treatment	 early	 during	 primary	 HIV	 infection,	 and	 were	 able	 to	maintain	viral	 control	 at	 least	 24	 months	 after	 treatment	 interruption	 (Saez-Cirion	 et	 al.,	2013).		These	HIV-infected	people	generally	had	small	HIV	reservoirs	in	PBMCs	and	less	 infection	of	 long-lived	subsets	of	resting	T	cells.	 	A	previous	study	had	similar	results	 in	 5	 PTCs	 who	 also	 initiated	 treatment	 during	 acute	 infection	 and,	 after	stopping	 therapy,	 sustained	viral	 control	 for	a	mean	of	77	months	 (Hocqueloux	et	al.,	 2010).	 	 While	 complete	 eradication	 of	 HIV-infected	 cells	 would	 be	 ideal,	 it	 is	practical	to	consider	the	goal	of	a	functional	cure,	which	could	theoretically	involve	
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viral	 suppression	 without	 therapy	 after	 clearance	 of	 just	 a	 fraction	 of	 reservoirs.			Additionally,	treatments	to	boost	immune	function	or	prevent	viral	immune	evasion,	as	with	a	Nef	 inhibitor,	may	be	 the	most	helpful	 to	allow	a	patient’s	own	 immune	defenses	to	effectively	control	HIV	replication.	
	
Additional	HIV	cure	strategies	The	 case	 of	 the	 Berlin	 patient	 renewed	 interest	 in	 stem	 cell	 therapy	 as	 a	potential	cure,	though	with	no	additional	successes	yet.		Indeed,	recent	studies	that	have	 examined	 the	 impact	 of	 bone	 marrow	 transplant	 have	 not	 replicated	 the	conditions	that	led	to	a	cure	of	the	Berlin	patient.		Cillo	et	al.	detected	plasma	virus	and	HIV	DNA	 in	 10	HIV-infected	people	 after	 they	had	 received	 autologous	BMTs	(Cillo	et	al.,	2013).	 	Two	other	HIV+	men	experienced	a	decline	of	peripheral	blood	HIV	reservoir	after	allogeneic	transplants	from	wild	type-CCR5+	donors	(Henrich	et	al.,	 2013).	 	After	a	 treatment	 interruption,	 they	had	undetectable	viral	 levels	 for	a	prolonged	 period,	 but	 eventually	 both	 experienced	 viral	 rebound	 (Check	 Hayden,	2013;	Henrich	et	al.,	2013).	Despite	 the	 failure	 of	 bone	 marrow	 transplants	 as	 a	 therapy	 so	 far,	 an	alternative	approach	is	to	transplant	genetically	modified	hematopoietic	stem	cells	to	allow	continued	production	of	immune	cells	that	are	resistant	to	infection.		Some	studies	have	used	genetic	approaches	that	delete	CCR5	or	insert	restriction	factors	into	 stem	 cells	 to	 prevent	 infection	 ((Walker	 et	 al.,	 2012),	 reviewed	 in	 (Zhen	 and	Kitchen,	2014)).		Gene	therapy	has	also	been	used	to	modify	T	cells.		In	a	preliminary	trial,	re-infusion	of	autologous	T	cells	that	had	been	edited	by	zinc-finger	nucleases	
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Chapter 2  
CD133+ HPCs harbor HIV genomes in a subset of 










Introduction		 Latent	 HIV	 infection	 represents	 a	major	 barrier	 to	 curing	HIV	 (Finzi	 et	 al.,	1999;	Zhang	et	al.,	1999).		When	HIV	establishes	a	latent	infection	within	a	cell,	the	DNA	 provirus	 integrates	 into	 the	 host	 cell’s	 genome	 but	 viral	 genes	 are	 not	transcribed	(reviewed	 in	(Geeraert	et	al.,	2008)).	 	The	 latently	 infected	cell	 is	 thus	indistinguishable	 from	 an	 uninfected	 cell	 and	 cannot	 be	 targeted	 by	 the	 immune	system	or	current	antiretroviral	therapies.		The	HIV	provirus	can	persist	in	this	state	for	the	lifetime	of	the	cell;	however,	it	can	also	be	reactivated	if	cellular	conditions	change,	 leading	 to	 the	 production	 of	 new	 virions	 and	 potentially	 new	 infection	events	 (reviewed	 in	 (Trono	 et	 al.,	 2010)).	 	 Thus,	 HIV	 replication	 will	 resume	 if	antiretroviral	 therapy	 is	 discontinued	 unless	 all	 latent	 reservoirs	 of	 virus	 are	eliminated.		 Although	resting	memory	CD4+	T	cells	are	a	well-studied	reservoir	for	latent	HIV,	not	all	HIV	sequences	in	the	plasma	of	many	successfully	treated	HIV+	donors	can	be	matched	 to	sequences	 in	peripheral	blood	CD4+	T	cells	 (Bailey	et	al.,	2006;	
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Brennan	 et	 al.,	 2009;	 Sahu	 et	 al.,	 2009).	 	 These	 data	may	 suggest	 that	 additional	reservoirs	of	virus	exist	and	contribute	to	residual	viremia	during	treatment	as	well	as	to	viral	rebound	upon	treatment	interruption	(Sahu	et	al.,	2009).		 Recently,	 we	 proposed	 that	 hematopoietic	 progenitor	 cells	 (HPCs)	 in	 the	bone	marrow	 serve	 as	 a	 reservoir	 for	 latent	HIV.	 	We	 assessed	HIV-1	 infection	 in	CD34+	HPCs	from	nine	HIV-infected	donors	with	undetectable	viral	loads	on	highly	active	antiretroviral	therapy	(HAART)	for	at	least	6	months	(Carter	et	al.,	2010).		In	four	of	nine	donors,	we	detected	HIV-1	proviral	genomes	in	CD34-sorted	cells	at	a	frequency	 of	 3-40	 genomes	 per	 10,000	 cells	 (Carter	 et	 al.,	 2010),	 suggesting	 that	HPCs	might	serve	as	a	reservoir	of	virus.		Comparable	amounts	of	HIV	DNA	were	not	observed	 in	 bone	 marrow	 cells	 immunodepleted	 for	 CD34	 (Carter	 et	 al.,	 2010).		However,	subsequent	studies	have	not	detected	HIV	genomes	in	CD34+	HPCs	from	donors	with	undetectable	viral	loads	(Durand	et	al.,	2012;	Josefsson	et	al.,	2012)	and	have	suggested	 that	HIV	genomes	 in	CD34+	samples	may	be	due	 to	contaminating	CD3+	T	cells	(Durand	et	al.,	2012).		 In	addition	to	detecting	HIV	genomes	in	CD34+	cells	ex	vivo,	we	have	shown	that	CD34+	cells	can	be	infected	by	CCR5-	and	CXCR4-tropic	HIV	in	vitro	(Carter	et	al.,	 2010).	 	 We	 also	 demonstrated	 that	 HPCs	 expressing	 CD133,	 a	 marker	 for	 an	immature	subset	of	CD34+	HPCs,	are	only	infected	by	CXCR4-utilizing	HIV-1	in	vitro	(Carter	 et	 al.,	 2011).	However,	HIV	 infection	 of	 CD133+	 cells	 in	 vivo	 has	 not	 been	assessed.		 To	investigate	whether	CD133+	HPCs	harbor	HIV-1	in	vivo,	we	quantified	HIV	proviral	genomes	 in	CD133+	HPCs	from	11	HIV+	donors	with	plasma	viral	 loads	of	
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<48	 copies/ml	 for	 at	 least	 6	months.	 	We	 furthermore	 analyzed	 the	 frequency	 of	CD3+	 T	 cells	 in	 each	 sample	 to	 assess	 whether	 HIV	 genomes	 could	 arise	 from	contamination	with	CD3+	cells.		
Results	
Donor	characteristics.	 	The	11	donors	in	this	study	had	been	diagnosed	with	HIV	infection	for	an	average	of	11.9	years	(standard	deviation	[s.d.]	8.1	years,	range	3	–	24	years)	 (Table	2-1).	 	Donors	had	viral	 loads	of	<48	copies	per	ml	 for	at	 least	6	months	(mean	4.1	years,	s.d.	2.7	years,	range	<1	–	8.4	years)	and	were	being	treated	with	 at	 least	 3	 active	 antiretroviral	 agents	 at	 the	 time	of	 bone	marrow	aspiration	(Table	2-1).	
	
Magnetic	 sorting	 for	 CD133	 minimizes	 T	 cell	 contamination.	 	 Bone	 marrow	mononuclear	cells	(BMMC)	from	each	donor	were	subjected	to	magnetic	sorting	for	CD133	 (Figure	2-1A),	 a	 surface	marker	 found	on	 a	 subset	 of	 CD34+	 cells	 (Figure	
2-1B).	 	 CD133	 and	 CD3	 expression	 on	 CD133-sorted	 and	 CD133-depleted	populations	was	analyzed	by	flow	cytometry	(Figure	2-1C).		Although	the	purity	of	the	CD133-sorted	populations	varied	 from	84.4	 to	98.9%	among	donors,	 less	 than	1%	of	 the	 cells	 in	 each	 CD133-sorted	 sample	were	 CD3+	 (Figure	2-1C	and	Table	
2-2).		By	contrast,	CD133-depleted	samples	contained	36-82%	CD3+	cells.				
CD133-sorted	 BMMCs	 contain	 HIV	 DNA.	 	 We	 used	 quantitative	 PCR	 (qPCR)	 to	determine	 the	 frequency	 of	 HIV	 genomes	 in	 CD133-sorted	 and	 CD133-depleted	
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samples.	Samples	were	at	 limiting	dilution	as	prepared,	with	no	more	 than	1/3	of	reactions	 yielding	 HIV	 amplification	 for	 any	 sample.	 	 Between	 4800	 and	 180,000	cells	were	 analyzed	 from	each	 sample.	 	HIV-1	DNA	was	detected	 in	CD133-sorted	samples	for	6	of	11	donors	and	in	CD133-depleted	samples	for	6	of	11	donors	with	0	-	3	total	copies	of	HIV	DNA	detected	per	sample	(Table	2-2).		The	frequency	of	cells	containing	 HIV	 DNA	 varied	 from	 <0.71	 to	 63	 per	 100,000	 cells	 for	 CD133-sorted	samples	and	from	<0.59	to	49	per	100,000	cells	for	CD133-depleted	samples	(Table	
2-2).	 		
CD3+	T	cells	are	unlikely	to	account	for	HIV	DNA	in	CD133-sorted	samples.	 	 If	the	HIV	genomes	detected	in	our	samples	derived	from	CD3+	cells,	we	would	expect	to	observe	many	more	HIV	genomes	in	the	CD133-depleted	samples,	which	contain	36-82%	CD3+	cells,	than	in	the	CD133-sorted	samples,	which	contain	less	than	1%	CD3+	 cells.	 	 However,	we	 instead	 observed	 that	 the	 frequency	 of	 HIV	 genomes	 in	CD133-sorted	 samples	was	 higher	 than	 the	 frequency	 of	 HIV	 genomes	 in	 CD133-depleted	samples	for	4	of	11	donors	(Table	2-2).	 	To	further	assess	the	possibility	that	 CD3+	 cell	 contamination	 accounted	 for	 the	HIV	 genomes	 observed	 in	 CD133-sorted	samples,	we	calculated	the	necessary	rate	of	CD3+	cell	infection	to	account	for	all	 the	 genomes	 detected	 in	 each	 sample	 (Figure	 2-2A).	 	 If	 all	 the	 HIV	 genomes	derived	from	CD3+	cells,	we	would	expect	these	calculated	frequencies	to	be	similar	in	 the	 CD133-depleted	 and	 CD133-sorted	 samples	 for	 each	 donor.	 However,	 we	found	that	for	five	of	the	six	positive	samples,	the	frequency	of	HIV	genomes	in	the	CD3+	cells	from	the	CD133-depleted	sample	was	approximately	100-fold	too	low	to	
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support	 this	 conclusion	 (Figure	 2-2A).	 	 Using	 Fisher’s	 exact	 test,	 we	 obtained	significantly	 discordant	 calculated	 rates	 of	 CD3+	 infection	 in	 the	 two	 samples	 for	donors	304000,	305000,	312101,	313212,	and	315214	(p	<	0.0001	(donor	315214)	or	 p	 <	 0.01	 (other	 donors)	 using	 mean	 estimates	 of	 CD3+	 cell	 number,	 p	 <	 0.01	(305000,	 312101,	 and	 315214)	 or	 p	 <	 0.05	 (304000	 and	 313212)	 using	conservative	 estimates;	 see	 Figure	 2-2A	 legend)	 (Figure	 2-2A).	 	 Donor	 311000	demonstrated	 the	 same	 trend	 but	 statistical	 significance	 was	 not	 achieved	 (p	 =	0.066	using	mean	estimates)	(Figure	2-2A).		We	therefore	conclude	that	for	at	least	5	of	the	6	donors	with	detectable	HIV	DNA	in	CD133-sorted	cells,	it	is	unlikely	that	the	HIV	DNA	detected	in	the	sorted	samples	comes	from	T	cell	contamination.				 It	 is	 also	 theoretically	 possible	 that	 CD133-,	 non-T	 cell	 contaminants	 could	account	for	the	genomes	detected	in	the	CD133-sorted	cells.		However,	a	calculation	analogous	 to	 the	 one	 described	 above	 revealed	 that	 CD133-	 contaminants	 were	unlikely	 to	 account	 for	 the	 genomes	 present	 in	 CD133-sorted	 samples	 for	 donors	305000,	 312101,	 and	 315214	 (p	 <	 0.05)	 (Figure	 2-2B).	 	 For	 donor	 313212,	 a	significant	difference	was	observed	using	mean	(p	<	0.05)	but	not	conservative	(p	=	0.0506)	estimates	of	CD133-	cell	number	(see	Figure	2-2A	legend).		Donors	304000	and	 311000	 demonstrated	 the	 same	 trend,	 but	 statistical	 significance	 was	 not	achieved	 (p	 =	 0.096	 (304000)	 or	 0.105	 (311000)	 using	mean	 estimates)	 (Figure	
2-2B).	 	We	therefore	conclude	that	CD133-	contaminants	are	an	unlikely	source	of	HIV	 genomes	 in	 the	 CD133-sorted	 samples	 from	 three	 of	 the	 six	 positive	 donors.		Importantly,	 the	 converse	 is	 also	 true:	 CD133+	 cells	 are	 an	 unlikely	 source	 of	genomes	 detected	 in	 the	 CD133-depleted	 sample	 (Table	 2-2).	 	 Thus,	 these	 data	
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suggest	that	at	least	two	separable	cellular	sources	can	contain	HIV	DNA	in	the	bone	marrow.		
HIV	sequencing	and	assessment	of	contamination.	 	 To	 assess	whether	 the	HIV	DNA	 detected	 arose	 from	 laboratory	 contamination,	 qPCR	 amplicons	 were	separated	from	the	primers	and	probe	by	gel	electrophoresis.		In	all	cases,	a	distinct	band	 of	 approximately	 120	 base	 pairs	 was	 observed,	 confirming	 amplification	(Figure	2-3A).	 	Amplicons	were	extracted	 from	the	gel,	 sequenced,	and	aligned	to	the	positive	control	(HXB2,	Figure	2-3B).			Analysis	of	HXB2	DNA	from	three	single	copy	reactions	amplified	alongside	donor	samples	revealed	that	all	three	sequences	were	 identical	and	agreed	with	 the	HXB2	reference	sequence.	 	 In	contrast,	no	 two	donors’	 samples	 yielded	 identical	 sequences.	 Unsurprisingly,	 we	 did	 observe	identical	 sequences	 within	 the	 CD133-sorted	 and	 CD133-depleted	 fractions	 from	the	 same	 donor	 (311000	 and	 315214).	 	 Compared	 with	 the	 HXB2	 sequence,	 the	numbers	 of	 differences	 observed	were	 similar	 to	 those	 observed	 in	 samples	 from	the	Los	Alamos	database	(Figure	2-3C).		Thus,	it	is	unlikely	that	the	positive	results	we	obtained	are	due	to	contamination	by	the	positive	control.		
Stability	of	HIV	DNA	in	HPCs	over	time.	 	As	noted	in	Table	2-1,	 four	donors	had	donated	samples	 for	prior	 studies	 (Carter	et	 al.,	 2011;	Carter	et	 al.,	 2010).	 	At	 the	time	of	the	previous	donation,	two	of	these	donors	(308103	and	312101)	had	high	viral	loads	(>50,000	copies/ml)	and	subsequently	started	therapy.	The	other	repeat	donors	(313212	and	315214)	had	undetectable	viral	 loads	at	 the	 time	of	previous	
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donation.	 	 In	 the	prior	study,	HIV	DNA	was	detected	 in	HPC	samples	 from	both	of	these	donors	(previously	referred	to	as	donors	12	and	14,	respectively	(Carter	et	al.,	2010)).		In	concordance	with	these	results,	we	also	detected	HIV	DNA	in	the	current	HPC	 samples,	 which	 were	 collected	 after	 an	 additional	 3.3	 years	 of	 suppressive	therapy.	 	 Thus,	 HIV	 infection	 of	 HPCs	 can	 be	 consistently	 detected	 in	 the	 same	donors	after	years	of	suppressed	viral	replication.		
Year	 of	 diagnosis	 is	 associated	 with	 detection	 of	 HIV	 DNA	 in	 CD133-sorted	
cells.	In	our	prior	study	we	had	noted	that	all	4	donors	with	detectable	HIV	DNA	in	progenitor	 cells	 were	 diagnosed	 relatively	 recently	 (2001	 or	 later)	 whereas	 the	three	donors	diagnosed	prior	to	2001	were	PCR	negative	(Carter	et	al.,	2010).	 	We	assessed	whether	 this	 trend	held	 in	 our	 current	 cohort	 and	observed	 that	 donors	with	positive	PCR	 results	were	diagnosed	 significantly	more	 recently	 than	donors	without	 detectable	 provirus	 in	 CD133-sorted	 samples	 (p	 <	 0.02,	 t-test)	 (Figure	
2-4A).	 	 	One	sample	 from	a	 recently	diagnosed	donor	was	negative	 in	 the	current	study	(308103),	but	as	only	14,000	cells	could	be	analyzed	from	this	donor	(Table	
2-2),	this	may	be	a	false	negative	result.	The	association	between	infection	of	HPCs	and	 year	 of	 diagnosis	 does	 not	 result	 from	 differences	 in	 the	 duration	 of	 viral	suppression	 (p	=	0.49,	 t-test)	 (Table	2-1	 and	Figure	2-4B)	or	 from	differences	 in	the	purity	of	CD133-sorted	samples	or	the	percentage	of	T	cells	present	(p	=	0.65	or	0.29,	respectively).		Neither	year	of	diagnosis	nor	duration	of	viral	suppression	was	related	 to	 detection	 of	 HIV	 DNA	 in	 CD133-depleted	 samples	 (Figure	 2-4C-D,	 p	 =	0.46	or	0.32,	respectively).	
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Discussion		 Because	 reservoirs	 of	 latent	 virus	 represent	 a	 barrier	 to	 curing	 HIV,	 it	 is	essential	 to	 identify	 all	 sources	 of	 persistent	 virus.	 	 We	 previously	 showed	 that	CD34+	HPCs	may	harbor	HIV	genomes	 in	donors	with	HIV	 loads	of	<48	copies/ml	(Carter	 et	 al.,	 2010);	 however,	 subsequent	 studies	 suggested	 that	 contamination	with	CD3+	cells	could	explain	our	results	(Durand	et	al.,	2012)	or	that	HIV	genomes	in	HPCs	may	not	persist	during	years	of	therapy	(Josefsson	et	al.,	2012).	 	Here,	we	extend	 our	 previous	 findings	 by	 showing	 that	 HIV	 can	 be	 detected	 in	 immature,	CD133+	HPCs	from	donors	who	have	had	undetectable	viral	loads	for	up	to	8	years,	including	 two	donors	where	we	had	detected	HIV	DNA	 in	CD34+	HPCs	 in	 samples	donated	 for	 our	 previous	 study	 3	 years	 earlier	 (Carter	 et	 al.,	 2010).	 We	 also	demonstrate	 that	 for	 5	 of	 6	 CD133-sorted	 samples	 where	 HIV	 genomes	 were	detected,	 CD3+	 cell	 contamination	 is	 a	 poor	 explanation	 for	 our	 results.	 	 These	findings	 demonstrate	 that	 HPCs,	 including	 CD133+	 HPCs,	 can	 harbor	 HIV	 DNA	during	years	of	therapy.	We	 estimate	 that	 the	 frequency	 of	 HIV	 genomes	 in	 CD133+	 HPCs	 in	 our	donors	is	<0.71-63	genomes	per	100,000	cells.		These	frequencies	are	similar	to	the	reported	 frequency	 of	 HIV	 genomes	 in	 peripheral	 blood	 CD4+	 T	 cells	 (1-100	 per	100,000	 cells	 (Chomont	 et	 al.,	 2009)).	 	 Consistent	with	 reports	 that	 bone	marrow	CD4+	T	cells	can	also	harbor	provirus	(Durand	et	al.,	2012),	we	observed	HIV	DNA	in	some	samples	depleted	for	CD133+	cells.		However,	our	analysis	was	not	designed	to	determine	the	type	of	CD133-	cell	that	was	infected.		
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For	 the	 two	 donors	 examined	 both	 here	 and	 in	 our	 prior	 study,	we	 found	higher	frequencies	of	HIV	DNA	in	HPCs	in	our	prior	study	(Carter	et	al.,	2010)	than	we	did	here.	 	However,	 for	both	donors	 the	95%	confidence	 intervals	 for	 the	 true	frequency	 of	 genomes	 in	 these	 cell	 populations	 are	 overlapping.	 	 These	 95%	confidence	 intervals	 are	 very	 broad	 because	 of	 the	 low	 number	 of	 detectable	genomes.	 	 Furthermore,	 our	 current	 study	 assesses	 the	 frequency	 of	 HIV	 DNA	 in	CD133+	cells	whereas	our	previous	study	examined	total	CD34+	cells.		It	is	not	clear	whether	the	frequency	of	HIV	genomes	in	these	two	HPC	subsets	differs.		Finally,	the	level	 of	 variation	observed	between	 the	 sequential	measurements	 from	 these	 two	donors	 is	 consistent	 with	 the	 variation	 among	 sequential	 measurements	 of	 HIV	frequency	in	resting	CD4+	T	cells	in	donors	with	suppressed	viral	loads,	even	though	this	reservoir	is	known	to	decay	very	slowly	with	a	half-life	of	~44	months	(Siliciano	et	 al.,	 2003).	 	 To	 better	 compare	 the	 number	 of	 genomes	 in	 CD34+	HPCs,	 CD133+	HPCs,	 and	 peripheral	 blood	 resting	 memory	 T	 cells,	 additional	 studies	 that	simultaneously	 compare	 HIV	 proviral	 DNA	 frequencies	 in	 all	 of	 these	 cell	populations	 from	 the	 same	 donor	 are	 needed.	 	 Further	 studies	 examining	 the	frequency	 of	 HIV	 genomes	 over	 time	 in	 the	 same	 HPC	 population	 from	 a	 larger	cohort	of	donors	are	also	required	to	understand	the	rate	at	which	HIV	genomes	in	HPCs	 decay	 over	 time	 and	 the	 contribution	 of	 these	 cells	 to	 long-term	 viral	persistence.	We	report	here	that	donors	with	evidence	of	 infected	HPCs	were	diagnosed	significantly	more	 recently	 than	donors	without	evidence	of	 infection.	 	This	 result	cannot	be	explained	by	a	shorter	period	of	suppressive	therapy	or	by	the	number	of	
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contaminating	CD3+	cells.		Instead,	we	hypothesize	that	individuals	with	high	levels	of	 HIV	 infection	 in	 HPCs	 are	 less	 likely	 to	 have	 survived	 or	maintained	 low	 viral	loads	 if	 they	were	diagnosed	prior	to	the	advent	of	HAART.	 	This	reduced	survival	might	 be	 due	 to	 higher	 levels	 of	 CXCR4-tropic	 virus,	which	we	 have	 shown	 to	 be	required	for	 infection	of	 immature	HPCs	 in	vitro	(Carter	et	al.,	2011)	and	which	 is	associated	with	more	rapid	disease	progression	(Connor	et	al.,	1997;	Karlsson	et	al.,	1994;	Scarlatti	et	al.,	1997;	Shepherd	et	al.,	2008;	Waters	et	al.,	2008;	Weiser	et	al.,	2008;	Yu	et	al.,	1998).		Alternatively,	the	inflammation	associated	with	chronic	high-level	viremia	may	influence	the	stability	of	HIV	genomes	in	HPCs.	 	Further	study	is	required	 to	 understand	 the	 connection	 between	 the	 frequency	 of	 HIV	 genomes	found	in	HPCs	and	year	of	diagnosis.	In	a	recent	study	by	Durand	et	al.,	which	failed	to	detect	evidence	of	infection	of	HPCs	in	optimally	treated	donors,	10	of	11	total	donors	were	diagnosed	prior	to	2001	and	5	of	11	donors	were	diagnosed	during	 the	1980s	 (Durand	et	 al.,	 2012).			Based	on	the	results	reported	here,	it	is	not	surprising	that	positive	results	were	not	achieved	 in	 this	 study.	 In	addition,	 the	protocol	used	by	Durand	et	al.	 included	an	overnight	 incubation	 in	 serum-containing	 media	 whereas	 our	 one-day	 protocol	utilized	media	optimized	 to	maintain	progenitors	 in	 an	undifferentiated	 state	 that	preserves	latent	infection	(McNamara	et	al.,	2012).	A	second	study	authored	by	Josefsson	et	al.,	also	failed	to	detect	evidence	of	HIV	 infection	 of	 HPCs	 in	 eight	 optimally	 treated	 donors	who	were	more	 recently	diagnosed.	 	 However,	 methodological	 differences	 may	 have	 contributed	 to	 these	negative	results.	 	Josefsson	and	colleagues	excluded	CD4+CD34+	cells	from	the	HPC	
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population	studied	(Josefsson	et	al.,	2012).		Because	we	have	previously	shown	that	CD4	 expression	 on	 HPCs	 is	 required	 for	 infection	 of	 HPCs	 in	 vitro	 (Carter	 et	 al.,	2011),	 the	 exclusion	 of	 CD4+CD34+	 cells	would	 exclude	 the	 CD34+	 cell	 population	most	 likely	 to	 contain	 HIV	 genomes.	 	 Furthermore,	 the	 primers	 used	 in	 our	 PCR	analysis	 are	 substantially	 more	 conserved	 than	 those	 used	 by	 Josefsson	 and	colleagues,	which	could	 limit	the	sensitivity	of	their	assay	to	detect	variable	donor	HIV	sequences.			 In	 vitro,	 CD133+	 HPCs	 are	 almost	 exclusively	 infected	 by	 HIV-1	 envelopes	that	use	CXCR4	as	a	coreceptor	(Carter	et	al.,	2011).		We	would	therefore	expect	that	at	 least	a	minor	population	of	CXCR4-tropic	virus	exists	 in	the	6	donors	 for	whom	we	detected	HIV	DNA	in	CD133-sorted	cells.		This	is	consistent	with	studies	showing	that	 isolates	predicted	 to	use	CXCR4	can	be	detected	as	a	minor	population	 in	12-50%	of	recently-infected	patients	(Abbate	et	al.,	2011;	Chalmet	et	al.,	2012;	Daar	et	al.,	 2007);	 furthermore,	 CXCR4-utilizing	 virus	 persists	 in	 patients	 on	 suppressive	therapy	 (Seclen	 et	 al.,	 2010;	 Soulie	 et	 al.,	 2007)	 and	may	 become	more	 prevalent	during	 therapy	 in	 some	patients	 (Delobel	 et	 al.,	 2005;	Hunt	 et	 al.,	 2006).	 	 Further	study	to	assess	HIV	envelope	tropism	in	our	cohort	is	needed	to	confirm	the	role	of	HIV	envelope	tropism	in	the	infection	of	HPCs	in	vivo.				 Our	results	demonstrate	that	HIV	genomes	can	be	detected	in	CD133+	HPCs	from	a	subset	of	donors	with	undetectable	viral	loads	and	that	the	genomes	detected	are	not	explained	by	contamination	with	CD3+	T	cells.	 	While	these	findings	do	not	prove	 that	 HPCs	 serve	 as	 a	 reservoir	 for	 HIV	 in	 these	 donors,	 as	 the	 genomes	detected	may	be	defective,	 they	do	 indicate	 that	HPCs	 can	 retain	HIV	DNA	during	
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years	 of	 successful	 antiretroviral	 therapy.	 	 We	 are	 currently	 investigating	 the	contribution	 of	 HIV	 genomes	 in	 HPCs	 to	 residual	 viremia	 in	 treated	 donors.		Meanwhile,	 strategies	 to	 reactivate	 latent	 virus	 from	 HPCs	 should	 be	 considered	alongside	 strategies	 that	 reactivate	 virus	 in	 resting	 memory	 T	 cells	 to	 develop	therapies	with	the	best	chance	of	eliminating	all	reservoirs	of	persistent	HIV.		
Methods	
Clinical	 Samples.	 	 The	 donor	 samples	 analyzed	 in	 this	 study	 are	 a	 consecutive	subset	of	our	cohort,	excluding	two	donors	where	the	CD133-sorted	sample	was	less	than	 80%	 pure	 and	 two	 donors	 where	 samples	 had	 been	 used	 up	 in	 prior	experiments	(1	sample)	or	lost	(1	sample).		We	recruited	HIV+	donors	currently	on	antiretroviral	 therapy	 from	 the	 University	 of	 Michigan	 HIV-AIDS	 Treatment	Program	and	obtained	 informed	 consent	 according	 to	 a	 protocol	 approved	by	 the	University	 of	 Michigan	 Institutional	 Review	 Board.	 	 At	 the	 time	 of	 aspiration,	 all	donors	were	over	 the	age	of	18,	had	normal	white	blood	cell	 counts,	 and	had	had	plasma	 viral	 loads	 of	 <48	 copies/ml	 for	 at	 least	 6	 months.	 	 Twenty	 ml	 of	 bone	marrow	was	aspirated	 from	the	posterior	 iliac	crest,	collected	 in	preservative-free	heparin,	and	processed	immediately.		
Isolation	 of	 CD133-sorted	 and	 CD133-depleted	 cells.	 	 Bone	 marrow	mononuclear	 cells	 (BMMC)	 were	 isolated	 by	 Ficoll-Paque	 density	 separation	 (GE	Healthcare).	 	Adherent	 cells	were	depleted	by	 incubation	 in	 serum-free	 StemSpan	media	 (STEMCELL	 Technologies)	 for	 two	 hours	 at	 37ºC,	 then	 CD133+	 cells	 were	
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isolated	 by	magnetic	 sorting	 (Miltenyi	 Biotec).	 	 Cells	were	 sequentially	 sorted	 on	two	columns	to	increase	purity.		BMMCs	that	flowed	through	the	first	column	were	collected	 as	 the	 CD133-depleted	 fraction.	 	 Samples	 were	 cryopreserved	 in	 10%	DMSO	in	fetal	bovine	serum	until	analysis.		
Flow	 cytometry.	 	 A	 fraction	 of	 each	 clinical	 sample	 was	 stained	 with	 R-phycoerythrin-conjugated	 anti-CD133	 (Miltenyi	 Biotec),	 allophycocyanin-conjugated	 anti-CD3	 (eBioscience),	 and	 7-Aminoactinomycin	 D	 (7-AAD).	 	 Healthy	donor	BMMCs	(AllCells)	were	stained	with	R-phycoerythrin-conjugated	anti-CD133,	R-phycoerythrin-Cy7-conjugated	 anti-CD34	 (BD),	 and	 7-AAD.	 	 Samples	 were	analyzed	on	a	BD	FACSCanto.		
PCR.	 	Cells	were	lysed	in	MagNA	Pure	DNA	Lysis/Binding	Buffer	(Roche)	and	DNA	was	 extracted	 using	 a	 MagNA	 Pure	 Compact	 System	 (Roche).	 	 HIV-1	 DNA	 was	quantified	 by	 two-step	 quantitative	 PCR	 (qPCR).	 	 In	 the	 first	 round,	 5µl	DNA	was	amplified	 in	 each	 of	 6	 to	 18	 25µl	 reactions	 containing	 2.5µl	 10x	 Expand	 Long	Template	Buffer	2,	1.875U	Expand	Long	Template	Enzyme	mix	(Roche),	400nM	of	primers	 1st-Gag-R	 (5’-CAATATCATACGCCGAGAGTGCGCGCTTCAGCAAG-3’)	 (HXB2	702-718)	 and	 2nd-LTR-F-univ	 (5’-GTGTIGAAAATCTCTAGCAGTGGC-3’)	 (616-639),	and	 500µM	 dNTPs.	 In	 some	 reactions,	 400nM	 of	 ß-actin	 primers	 ß-actin-F	 (5’-CCTTTTTTGTCCCCCAACTTG-3’)	 and	 ß-actin-R	 (5’-TGGCTGCCTCCACCCA-3’)	 were	also	added.	The	5’	18	bases	of	1st-Gag-R	are	a	tag	used	in	the	second	round	of	PCR.	
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	 ACH-2	(Clouse	et	al.,	1989)	cell	DNA	diluted	in	DNA	from	uninfected	primary	HPCs	or	peripheral	blood	mononuclear	cells	(PBMCs)	to	a	concentration	of	10	HIV	genomes/µl	 or	 0.2	 genomes/µl	 were	 used	 as	 positive	 controls	 and	 controls	 for	sensitivity,	 respectively.	 DNA	 from	 uninfected	 HPCs	 or	 PBMCs	 was	 used	 as	 a	negative	control.		Thermocycling	was	conducted	using	a	thermocycler	preheated	to	93ºC	with	the	following	cycling	conditions:	93ºC	for	2	minutes;	12	cycles	of	93ºC	for	15	seconds,	60ºC	for	30	seconds,	68ºC	for	1	minute;	and	a	final	1	minute	at	68ºC.		 Second	round	qPCR	reactions	were	conducted	in	triplicate,	each	using	2µl	of	the	first	round	in	a	50µl	reaction.		Reactions	contained	25µl	FastStart	TaqMan	Probe	Master	2x	Master	Mix	(Roche),	1µM	each	of	primers	2nd-LTR-F-univ	and	2nd-Tag-R	(5’-CAATATCATACGCCGAGAGTGC-3’),	 and	 250nM	 Gag-probe-2	 (5’-FAM-CGCTTCAGCAAGCCGAGTCCTGC-BHQ-1-3’)	 (Biosearch	 Technologies).	 	 Reactions	were	 run	 and	 analyzed	 on	 an	 Applied	 Biosystems	 7300	 thermocycler	 with	 the	following	 cycling	 conditions:	 95ºC	 for	 10	 minutes,	 then	 45	 cycles	 of	 95ºC	 for	 15	seconds	followed	by	60ºC	for	60	seconds.		 Second	round	qPCR	reactions	to	amplify	ß-actin	were	conducted	to	validate	cell	counts.		Conditions	were	identical	to	those	listed	for	HIV-1	qPCR	except	that	the	ß-actin-F	 and	 ß-actin-R	 primers	 and	 a	 ß-actin	 probe	 (5’-FAM-CCCAGGGAGACCAAAAGCCTTCATACA-BHQ-1-3’)	 (Biosearch	 Technologies)	 were	used.	
	
DNA	 sequencing.	 	 Positive	 qPCR	 reactions	 were	 run	 on	 a	 2%	 agarose	 gel,	 the	amplicon	 excised,	 and	 the	 DNA	 extracted	 (QIAquick	 Gel	 Extraction	 Kit,	 Qiagen).		
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Amplicons	 were	 sequenced	 by	 Sanger	 dideoxy	 sequencing	 and	 analyzed	 using	4Peaks	(Mekentosj),	EditSeq	(DNAStar),	and	MEGA	5.05.	
	
Statistics.	95%	confidence	intervals	(CIs)	for	cell	counts	were	generated	using	Excel	2004	(Microsoft).		95%	CIs	for	the	fraction	of	cells	that	were	CD133+	and	CD3+	were	generated	 using	 a	 95%	 CI	 generator	 for	 binomial	 distributions	(statpages.org/confint.html).	 	 Fisher’s	 exact	 test	 was	 performed	 using	 an	 online	calculator	 (www.langsrud.com/fisher.htm).	 Mann	 Whitney	 and	 t-tests	 were	performed	using	GraphPad	Prism	5.0a.		 	 	
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Time on ART 
with VL < 50 
copies per ml 
(years) 
CD4 count 










303000 1990 1.0 1026 4.5 15.9 No 
304000 2004 3.3 533 4.8 9.35 No 
305000 2007 > 0.5 1421 6.4 15.4 No 
306000 1986/1987 3.4 1039 9.4 11.4 No 
307000 1992 5.8 829 8.0 20.7 No 
308103 2008 1.6 852 5.3 5.05 Yes (3) 
311000 1999 8.2 564 7.2 6.25 No 
312101 2006 2.2 812 7.5 8.75 Yes (1) 
313212 2002 8.4 466 4.0 9.00 Yes (12) 
314000 Late 1980’s 5.1 543 7.6 4.22 No 
315214 2006 5.0 850 6.3 4.11 Yes (14) 
1Number in parentheses indicates the donor number in reference (Carter et al., 
2010).   
















Frequency of HIV 
genomes per 105 cells 
in vivo (95% CI) 
CD133-sorted     
303000 14  
(9.7 – 17) 
98.8  
(98.4 – 99.0) 
0.05  
(0.01 – 0.14) 
0 <0.71  
(0 – 3.8) 
304000 2.7  
(2.4 – 3.0) 
84.4  
(81.6 – 86.9) 
0.80  
(0.29 – 1.7) 
1 3.7  
(0.084 – 23) 
305000 6.0  
(5.6 – 6.4) 
94.1  
(93.3 – 94.9) 
0.59  
(0.36 – 0.89) 
1 1.7  
(0.040 – 9.9) 
306000 5.4  
(4.8 – 6.0) 
94.3  
(93.5 – 95.0) 
0.62  
(0.39 – 0.94) 
0 <1.9  
(0 – 7.7) 
307000 12  
(11 – 13) 
93.2  
(92.5 – 93.8) 
0.22  
(0.12 – 0.38) 
0 <0.83  
(0 – 3.3) 
308103 1.4  
(1.0 – 1.7) 
92.1  
(90.2 – 93.8) 
0.23  
(0.03 – 0.82) 
0 <7.1  
(0 – 37) 
311000 4.1  
(3.6 – 4.5) 
97.7  
(97.1 – 98.3) 
0.83  
(0.51 – 1.3) 
1 2.5  
(0.057 – 15) 
312101 8.4  
(5.9 – 11) 
98.9  
(98.7 – 99.1) 
0.06  
(0.02 – 0.15) 
1 1.2  
(0.023 – 9.5) 
313212 5.4  
(4.3 – 6.5) 
98.4  
(98.0 – 98.7) 
0.29  
(0.16 – 0.48) 
1 1.9  
(0.039 – 13) 
314000 0.96  
(0.83 – 1.1) 
85.8  
(81.4 – 89.5) 
0.65  
(0.08 – 2.3) 
0 <10.4  
(0 – 44) 
315214 0.48  
(0.35 – 0.61) 
92.4  
(89.4 – 94.8) 
0.76  
(0.16 – 2.2) 
3 63  
(10 – 250) 
CD133-depleted     
303000 18  
(13 – 23) 
5.0  
(4.0 – 6.2) 
36  
(34 – 38) 
2 1.1  
(0.11 – 5.7) 
304000 4.0  
(3.6 – 4.3) 
0.18  
(0.01 – 1.5) 
61  
(56 – 66) 
0 <2.5  
(0 – 10) 
305000 17  
(14 – 20) 
0.13  
(0.03 – 0.43) 
52  
(50 – 54) 
0 <0.59  
(0 – 2.7) 
306000 1.8  
(1.7 – 2.0) 
0.31  
(0.08 – 1.1) 
73  
(70 – 76) 
0 <5.6  
(0 – 22) 
307000 13  
(12 – 14) 
1.6  
(1.0 – 2.4) 
43  
(40 – 46) 
1 0.77  
(0.017 – 4.8) 
308103 1.1  
(0.90 – 1.2) 
<0.19  
(0 – 0.69) 
75  
(71 – 79) 
2 19  
(2.0 – 80) 
311000 2.5  
(2.1 – 2.9) 
<0.20  
(0 – 0.74) 
58  
(54 – 63) 
2 8.1  
(0.84 – 35) 
312101 5.4  
(4.7 – 6.0) 
<0.30  
(0 – 1.1) 
44  
(38 – 49) 
0 <1.9  
(0 – 7.8) 
313212 3.1  
(2.4 – 3.8) 
<0.15  
(0 – 0.55) 
59  
(55 – 63) 
0 <3.2  
(0 – 15) 
314000 0.54  
(0.42 – 0.66) 
<0.21  
(0 – 0.76) 
82  
(78 – 85) 
1 19  
(0.38 – 130) 
315214 0.41  
(0.32 – 0.50) 
<0.22  
(0 – 0.79)  
81  
(77 – 84) 
2 49  
























A,	Comparison	of	the	mean	year	of	diagnosis	of	donors	with	or	without	detectable	HIV	DNA	in	CD133-sorted	cells.		*	p	<	0.02,	t-test.		Lines	indicate	mean	and	standard	error;	symbols	indicate	individual	values.		Conservative	estimates	of	the	year	of	diagnosis	were	used	in	cases	where	the	year	of	diagnosis	was	not	known	precisely	(1987	for	donor	306000	and	1989	for	donor	314000).		B,	Comparison	of	the	mean	length	of	time	that	viral	load	in	the	plasma	has	been	undetectable	in	donors	with	or	without	detectable	HIV	DNA	in	CD133-sorted	cells.		The	difference	between	the	two	groups	is	not	significant	(p	=	0.49,	t-test).		Lines	indicate	the	mean	and	standard	error;	symbols	indicate	individual	values.		A	conservative	estimate	of	0.5	years	for	time	that	the	viral	load	in	the	plasma	had	been	undetectable	was	used	for	donor	305000.	C, As A, but with donors grouped by whether HIV DNA was detected in 
CD133-depleted cells.  The difference between the two groups is not significant (p = 
0.46, t-test).  D, As B, but with donors grouped by whether HIV DNA was detected in 





































Chapter 3  
In vivo persistence of CCR5-tropic HIV in long-












CD133	marks	a	subset	of	HSPCs	that	is	enriched	for	HSCs	To	better	understand	which	 types	of	HSPCs	are	 infected	by	HIV	 in	vivo,	we	used	 a	 sequential	 purification	 protocol	 that	 separated	 two	 populations	 of	 HSPCs	from	 bone	 marrow	 aspirates	 from	 optimally	 treated	 HIV-infected	 people	 with	clinically	undetectable	circulating	plasma	virus	 for	at	 least	6	months	and	up	 to	11	years	 (Table	3-1).	 The	 first	 purification	 step	utilized	 two	passes	 over	 anti-CD133	magnetic	bead	 columns	 (Figure	3-1a,b),	which	 isolated	HSPCs	with	high	 levels	of	both	HSPC	markers,	CD34	and	CD133	(Sort	1,	Figure	3-1b,c).	The	flowthrough	from	this	 column	was	 passed	 over	 anti-CD34	magnetic	 bead	 columns	 twice	 to	 recover	cells	 that	 were	 CD34+	 but	 had	 insufficient	 CD133	 to	 efficiently	 bind	 to	 the	 anti-CD133	column	(Sort	2,	Figure	3-1a-c).		Compared	with	 Sort	 2,	 cells	 from	 Sort	 1	were	 strikingly	 enriched	 for	HSCs	and	 MPPs	 and	 depleted	 for	 more	 restricted	 progenitors	 (CMPs	 and	megakaryocyte/erythrocyte	 progenitors	 (MEPs),	 Figure	 3-1d-j,	 Figure	 3-2a)	(Doulatov	et	al.,	2010).	GMP/B-NKs	were	found	at	similar	frequencies	in	both	sorts	(Figure	3-1d,e).		Methylcellulose	colony	formation	assays,	which	allow	the	characterization	of	progenitor	 cells	 based	 on	 their	 clonogenic	 capacity	 and	 differentiation	 potential,	revealed	 similar	 numbers	 and	 types	 of	multipotent	 progenitors	 in	 both	 cell	 sorts	
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CD3+	T	cells	are	unlikely	to	account	for	HIV	DNA	in	HSPCs	If	the	HIV	genomes	detected	in	our	samples	derived	from	contaminating	CD3+	T	cells,	we	would	expect	to	observe	many	more	HIV	genomes	in	the	CD133	and	CD34-depleted	samples	(Flowthrough	1	and	Flowthrough	2),	which	are	composed	of	66%–68%	CD3+	T	cells,	than	in	the	sorted	samples,	which	are	composed	of	0.0%-1.6%	CD3+	T	cells.	However,	this	was	not	observed	().	We	used	these	values	to	calculate	the	rate	of	CD3+	T-cell	contamination	needed	to	account	for	all	of	the	genomes	detected	in	each	HSPC	sample	and	compared	that	to	the	actual	frequency	of	CD3+	T	cells	(McNamara	et	al.,	2013).	Using	Fisher's	exact	test,	we	obtained	significantly	discordant	calculated	rates	for	37	amplicons	().	For	one	sample,	we	did	not	have	T	cell	frequency	data	and,	for	four	samples,	the	p	values	for	this	analysis	values	were	>0.05	().		Thirty-two of the 37 had p values that were significant based on 
our most conservative estimate in which the top of the 95% confidence interval for the 
calculated infection rate in the CD3+ T cells in the flowthrough sample was compared 
with the bottom of the 95% confidence interval for the calculated infection rate in CD3+ 
T cells in the sorted sample (McNamara et al., 2013). All Sort 1 amplicons that were 
verified had less than or equal to 0.5% CD3+ T cells.  One verified Sort 2 amplicon had 








generated	env	amplicons	from	peripheral	blood	mononuclear	cells	(PBMCs)	from	all	23	donors.	 Interestingly,	all	donors	 that	harbored	CXCR4-tropic	HIV	 in	HSPCs	also	had	detectable	PBMC	provirus	predicted	to	be	CXCR4-tropic.	Because	geno2pheno	was	developed	with	subtype	B	sequences	and	predictions	for	non-subtype	B	sequences	are	less	reliable	(Garrido	et	al.,	2008;	Lee	et	al.,	2013;	Mulinge	et	al.,	2013),	we	verified	Env	tropism	with	a	phenotypic	assay.		For	this	analysis,	we	used	either	HSPC-derived	full-length	Env	or	a	non-HSPC-derived	Env	with	identical	nucleotide	or	amino	acid	V3	region	from	the	same	donor	as	available	(Table	3-3,	Figure	3-4,	Table	3-4).	Our	assay	confirmed	that	all	env	co-receptor	usage	predictions	were	correct.	Interestingly,	infection	with	six	Envs	could	not	be	fully	inhibited	by	receptor	blockade	in	Molt4-CCR5	cells	or	in	murine	3T3	cells	in	which	infection	completely	depends	on	expression	of	human	CD4	and	human	CCR5	(Deng	et	al.,	1997)	(Table	3-3,	Figure	3-4,	Table	3-4).	This	is	most	likely	due	to	resistance	of	patient	Envs	to	these	drugs	as	has	been	described	previously	(Delobel	et	al.,	2013;	Seclen	et	al.,	2010;	Soulie	et	al.,	2008).					
	CCR5-tropic	HIVs	target	HSPCs	that	are	unlikely	to	be	HSCs	Because	 our	 studies	 demonstrated	 the	 surprising	 result	 that	 HSPCs	harboring	 CCR5-utilizing	 virus	 persist	 in	 HIV-infected	 people	 and	 prior	 dogma	indicated	 only	 bona	 fide	 stem	 cells	 persist	 long-term,	 we	 pursued	 evidence	 that	CCR5-tropic	HIVs	may	still	target	HSCs.	To	assess	HIV	receptor	expression	in	HSCs,	we	used	a	publicly	available	microarray	dataset	of	RNA	expression	in	human	bone	marrow	HSPCs	 (Rapin	 et	 al.,	 2014)	 and	performed	 an	RNA-seq	 analysis	 of	mouse	
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bone	 marrow	 HSPCs.	 After	 confirming	 that	 the	 progenitor	 subsets	 expressed	 a	developmentally	 appropriate	 set	 of	 genes	 (Figure	 3-5a,b),	 we	 determined	 that	CCR5	was	expressed	at	 low	 levels	 in	HSCs	of	both	species	and	was	expressed	 to	a	greater	extent	in	more	differentiated	progenitor	subsets,	although	significance	was	not	 achieved	 in	 every	 case	 (Figure	 3-6a).	 These	 results	 compare	 with	 published	studies	showing	low	or	no	expression	of	CCR5	protein	by	HSC-enriched	cells	(Carter	et	 al.,	 2011;	 Carter	 et	 al.,	 2010)	 and	 limited	 expression	 of	 CCR5	 protein	 in	 more	differentiated	progenitors	 (Carter	et	al.,	2010;	Nixon	et	al.,	2013).	 	 In	addition,	we	found	that	CXCR4	and	CD4	RNA	was	expressed	across	the	subsets,	although	human	HSCs	had	the	highest	CD4	expression	of	all	 the	human	progenitor	subsets	(Figure	
3-6a).					 We	 confirmed	 protein	 expression	 data	 by	 assessing	 infection	 of	 HSC-enriched	 progenitors	 by	 full-length	 HIV-1s	 (Figure	 3-6b).	 	 CD133bright	 cell	populations	contain	 the	vast	majority	of	HSCs	based	on	engraftment	 in	NOD/SCID	mice	 (de	Wynter	 et	 al.,	 1998;	 Gorgens	 et	 al.,	 2013)	 and	 CD38,	 CD45RA	 and	 CD90	staining	(Figure	3-6c),	and	thus	we	used	the	 level	of	CD133	staining	to	assess	the	propensity	 of	 each	 HIV	 to	 target	 HSCs.	 	 To	 verify	 the	 co-receptor	 usage	 of	 our	viruses	in	HSPCs,	we	demonstrated	that	infection	by	NL4-3,	a	CXCR4-utilizing	virus,	was	 fully	 blocked	 by	 AMD3100	 (Figure	 3-6d,	 middle	 panels).	 Additionally,	maraviroc	blocked	infection	of	HSPCs	by	YU2,	a	CCR5-utilizing	virus	(Figure	3-6d,	right	panels).	Consistent	with	prior	experiments	performed	using	viral	pseudotypes	(Carter	et	al.,	2011),	the	CCR5-tropic	YU2	isolate	only	infected	progenitors	that	were	depleted	of	 stem	cells	 (low	 levels	of	CD133	and	CD90),	whereas	 the	CXCR4	 tropic	
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virus	targeted	a	wide	range	of	progenitors,	including	those	that	are	likely	to	be	stem	cells	(Figure	3-6d);	 indeed,	we	noted	4.5	times	more	CD133	expression	on	HSPCs	infected	by	wild	type	NL4-3	compared	with	YU2	(Figure	3-6e,f).	To	rule	out	latent	infection	 in	 stem	 cells,	 we	 treated	 with	 TNF-α,	 which	 activates	 latent	 infection	(McNamara	et	al.,	2012)	without	apparent	change	in	the	pattern	of	infection	(Figure	
3-5c,d).	Based	on	this	analysis,	CCR5-tropic	HIVs	are	restricted	to	progenitors	that	are	unlikely	to	be	HSCs	in	vitro.			
CCR5-tropic	 HIV	 targeting	 of	 non-stem	 cell	 progenitors	 is	 a	 conserved	
property	extending	to	a	transmitted/founder	virus		 Because	 there	 is	 evidence	 that	 the	 latent	 reservoir	 in	 vivo	 is	 established	during	acute	infection,	we	tested	additional	envelope	proteins	including	one	from	a	transmitted/founder	virus	[SVPB16	(SV16)]	(Carter	et	al.,	2011;	Li	et	al.,	2005;	Yam	et	al.,	2002)	for	their	ability	to	target	stem	cells	(Figure	3-7a,b).	For	these	studies,	we	utilized	 the	minimal	HIV	construct	 (HIV-7SF-GFP)	pseudotyped	such	 that	each	HIV	 Env	 protein	 decorates	 HIV	 viral-like	 particles	 containing	 a	 lentiviral	 genome.	Again,	we	found	that	all	CCR5-tropic	envelopes	differed	from	CXCR4-utilizing	ones	in	that	transduction	with	CCR5-tropic	envelopes	was	restricted	to	HSPCs	that	were	unlikely	to	be	HSCs	based	on	CD133	expression	(Figure	3-7c-e).	In	contrast,	viruses	pseudotyped	with	vesicular	stomatitis	virus	glycoprotein	(VSVG),	which	has	a	broad	tropism	 due	 to	 a	 ubiquitously	 expressed	 receptor	 (Finkelshtein	 et	 al.,	 2013),	infected	all	types	of	HSPCs	in	a	pattern	that	was	similar	to	viruses	pseudotyped	with	CXCR4-	 and	 dual-tropic	 viruses	 (Figure	3-7d).	 Collectively,	 these	 data	 extend	 the	
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conclusion	 that	CCR5-tropic	 viruses,	 including	one	 isolated	during	 acute	 infection,	are	largely	restricted	to	non-stem	cell	HSPCs.		
CCR5-	 and	 CXCR4-utilizing	 viruses	 target	 a	 separable	 population	 of	
multipotent	HSPCs	that	have	high	levels	of	CD4	The	HIV	 receptor	 CD4	 is	 required	 for	 infection	 and	 is	 expressed	 on	 CD34+	HSPCs,	although	at	low	levels	compared	to	CD4+	T	cells	(Louache	et	al.,	1994;	Zauli	et	 al.,	 1994).	 To	 determine	 whether	 CD4	 expression	 marks	 an	 HIV-susceptible	subset	 of	HSPCs,	we	measured	 CD4	 expression	 on	HSPCs	 transduced	with	 a	 GFP-expressing	lentiviral	vector	pseudotyped	with	CCR5-	or	CXCR4-tropic	Env	proteins	(Figure	 3-7a,b).	 Remarkably,	 we	 observed	 that	 HSPCs	 within	 a	 CD4high	 flow	cytometric	 gate	 displayed	 2-30	 times	 greater	 infection	 than	 CD4low/-	 cells	 (Figure	
3-8a-c).	 In	 contrast,	 VSVG-pseudotyped	 viruses	 demonstrated	 no	 such	 preference	(Figure	 3-8b).	 Additionally,	 CCR5-tropic	 envelopes	 had	 a	 significantly	 greater	propensity	 to	 target	 CD4high	 progenitors	 compared	 to	 CXCR4	 and	 dual-tropic	envelopes	(Figure	3-8b,c).		
	 To	determine	whether	 CD4	marks	 a	 stable	 and	 separable	HSPC	 subset,	we	asked	whether	fluorescence	activated	cell	sorting	(FACS)	could	separate	Sort	1	and	Sort	 2	 HSPCs	 into	 CD4high	 and	 CD4low	 populations.	 Indeed	 we	 found	 that	 these	populations	could	be	separated	(Figure	3-9a)	and	we	found	that	both	populations	had	similar	capacities	to	form	GEMM,	granulocyte/macrophage	(GM),	and	erythroid	(E)	 colonies	 (Figure	 3-9b,c).	 However,	 CD4high	 HSPCs	 contained	 a	 significantly	higher	 frequency	 of	 HSCs	 and	 MPPs	 (CD38-CD10-CD45RA-)	 than	 CD4low	 HSPCs	
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(Figure	3-10a,b,	Figure	3-11a)	 and	 this	 difference	was	 apparent	 for	 both	 Sort	 1	and	 Sort	 2	 cells.	 In	 contrast,	 CD4low/-	 HSPCs	 contained	 a	 significantly	 higher	frequency	of	the	more	differentiated	progenitors	[CMPs	and	MEPs	(Figure	3-11a)].	Interestingly,	 CD133bright	 Sort	 1	HSPCs	 had	 significantly	 higher	 levels	 of	 CD4	 than	CD133dim	 HSPCs	 from	 the	 same	 sorting	 protocol	 (Figure	 3-10c).	 Thus,	 higher	expression	of	CD4	and	CD133	mark	populations	enriched	 for	HSCs	and	MPPs	and	provide	a	mechanism	through	which	HIV	can	target	these	cells.	
 
CD4-negative lineages harbor HIV proviruses, some of which are identical to HSPC 
provirus 
 To determine whether HIV can be transmitted from infected HSPCs to progeny 
hematopoietic lineages via proliferation and differentiation rather than direct infection in 
vivo, we asked whether CD4-negative HSPC progeny might be recipients of clonal 
provirus from an infected progenitor.  For this analysis, we used fluorescence activated 
cell sorting (FACS) to isolate CD19+ B cells, CD8+ T cells and CD56+ natural killer (NK) 
cells.  To reduce the possibility of contamination by CD4-expressing cells, we depleted 
CD4+ cells using an anti-CD4 magnetic bead column prior to FACS. Post-sort analysis 
revealed low CD4+CD3+ T cell levels after bead depletion and prior to FACS (indicated 
as “pre” in Figure	 3-11b).  Post-FACS, CD4+CD3+ T cell contamination in the sorted 
lineages ranged from 0-0.12%.  In addition, we confirmed that the lineage-positive cells 
that we isolated were CD4-negative (indicated as “post” in Figure	3-11b).  
From approximately one million cells of each type analyzed, we detected provirus 
in CD4-negative cells from four of five donors with CXCR4-tropic HIV and only one of 
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five donors without detectable CXCR4-tropic virus. Notably, for donor 420000, we 
amplified an 839bp gag amplicon from the CD56+ NK population that was identical to an 
amplicon isolated from 420000 Sort 1 HSPCs (Fig. 5c, Table S4). Remarkably, for donor 
431000, we amplified identical env amplicons predicted to use CCR5 from multiple 
CD4-negative lineages, all of which shared identity with a CD133+ HSPC from Sort 1 
(Figure	 3-11c,d). Donor 431000 is unusual in our cohort in that they were diagnosed in 
the 1980s and had a persistently low CD4 count despite years of suppressive therapy 
(Table	3-1). 
It is important to note that we used a phylogenetic analysis to ensure that all 
included sequences were more similar to sequences from the same donor than to those 
from a different donor or lab strain.  In addition, we verified that amplicons from CD4-
negative lineages were unlikely to have come from contaminating CD3+CD4+ T cells. 
However, for donor 431000 we could not rule out the possibility that the amplicons from 
the CD19+ and CD56+ populations might have come from contaminating CD8+ cells.  	
Discussion	To	 cure	 HIV	 infection,	 all	 persistent	 cellular	 reservoirs	 of	 HIV	 must	 be	identified	 and	 eliminated,	 including	 potential	 reservoirs	 in	 bone	 marrow	 HSPCs.	While	 prior	 studies	 suggested	 that	 only	 CXCR4-tropic	 viruses,	 which	 had	 the	capacity	to	 infect	bona	fide	stem	cells,	potentially	established	long-term	reservoirs	in	HSPCs	 in	vivo	(Carter	et	al.,	2011),	here	we	provide	evidence	 that	non-stem	cell	CD34+	 progenitors	 infected	 by	 CCR5-tropic	 viruses	 are	 also	 long-lived.	 	 First,	 we	confirmed	and	extended	the	prior	conclusion	that	CCR5-tropic	viruses	preferentially	
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target	a	subset	of	HSPCs	that	are	unlikely	to	be	HSCs	(Carter	et	al.,	2011;	Nixon	et	al.,	2013).	Second,	we	demonstrated	that	provirus	recovered	from	HSPCs	isolated	from	HIV-infected	 people	 treated	with	 cART	 for	 up	 to	 11	 years	was	 often	 CCR5-tropic.	Finally,	 we	 demonstrated	 that	 HIV	 provirus	 could	 be	 recovered	 with	 similar	frequencies	 from	HSPC	populations	 that	 include	bona	 fide	 stem	 cells	 (Sort	 1)	 and	HSPC	 populations	 depleted	 for	 stem	 cells	 (Sort	 2).	 In	 sum,	 our	 results	 provide	evidence	 that	non-stem	cell	progenitors	 targeted	by	viruses	of	both	 tropisms	may	form	 long-lived	 reservoirs	 of	 HIV	 provirus	 in	 bone	 marrow	 HSPCs	 of	 optimally	treated	people.		While	 HSCs	 are	 the	 main	 drivers	 for	 reconstitution	 of	 all	 hematopoietic	lineages	in	xenograft	models,	new	insights	in	animal	and	human	disease	models	(e.g.	aplastic	 anemia)	have	 shown	contributions	of	non-stem	cell	 progenitors	 to	 steady	state	hematopoiesis	over	long	periods	of	time	(Busch	et	al.,	2015;	Notta	et	al.,	2016;	Sun	et	al.,	2014).	Non-stem	cell	progenitors	appear	to	survive	longer	than	previously	thought	 in	 the	 bone	marrow	without	 contribution	 from	HSCs,	 with	 non-stem	 cell	clones	sequentially	recruited	over	time	to	produce	mature	blood	cells	(Busch	et	al.,	2015;	Kim	et	al.,	2014;	Notta	et	al.,	2016;	Sun	et	al.,	2014;	Wu	et	al.,	2014).	While	we	expect	CCR5-tropic	provirus	is	harbored	by	non-stem	cell	progenitors,	our	data	also	indicate	that	a	CCR5-tropic	virus	can	infect	an	HSPC	that	produces	clonal	progeny	of	multiple	lineages.	Whether	 non-CD4+	 lineages	 harboring	 proviral	 genomes	 are	 capable	 of	generating	 infectious	 virus	 will	 require	 further	 study.	 Because	 wild	 type	 HIV	infection	is	toxic	to	differentiating	HSPCs	(Carter	et	al.,	2010),	it	is	possible	that	only	
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HSPC	harboring	defective	proviral	genomes	will	be	able	to	generate	viable	progeny.	Nevertheless,	detection	of	 identical	proviral	sequences	 in	HSPCs	and	CD4-negative	lineages	 supports	 our	 conclusions	 that	 hematopoietic	 progenitors	 capable	 of	producing	 daughter	 cells	 that	 develop	 into	 multiple	 lineages	 (1)	 express	 HIV	receptors,	(2)	can	be	infected	by	HIV	in	vivo	and	(3)	endure	for	years.	If	non-HSC	progenitors	persist,	the	prevalence	of	CCR5	in	this	compartment	is	not	surprising.	During	acute	infection	when	circulating	virus	peaks,	the	majority	of	virus	 is	CCR5-tropic	 (Zhu	et	al.,	1993).	Moreover,	 rebounding	virus	 shows	 little	evolution	 from	virus	present	 before	 the	 initiation	 of	 cART,	 further	 supporting	 the	hypothesis	that	the	genetically	uniform	populations	of	circulating	virus	seen	during	cART	 and	 when	 cART	 is	 interrupted	 derive	 from	 a	 few	 long-lived	 cells	 that	 are	infected	 pre-therapy	 (Kearney	 et	 al.,	 2014).	However,	we	 also	 detected	 persistent	provirus	that	encodes	Env	proteins	capable	of	utilizing	CXCR4	to	enter	cells,	which	can	more	efficiently	target	HSCs	(Carter	et	al.,	2011).	Given	that	transmitting	virus	is	nearly	uniformly	CCR5-tropic,	 these	data	suggest	that	a	significant	number	of	cells	harboring	persistent	provirus	are	 infected	by	a	virus	minority	 that	evolved	 to	use	CXCR4	for	infection	by	the	time	therapy	began	and	was	archived	in	both	PBMCs	and	HSPCs.		Finally,	we	 identified	 a	 sub-population	of	 CD4+	HSPCs	 that	 is	 preferentially	targeted	 by	 both	 CXCR4-tropic	 and	 CCR5-tropic	 viruses	 and	 we	 show	 that	 this	subset	 is	 enriched	 for	 HSCs	 and	 multipotent	 progenitors.	 These	 results	 are	consistent	 with	 other	 studies	 investigating	 the	 lineage	 potential	 of	 CD4	 subsets	using	functional	assays	(Louache	et	al.,	1994;	Muench	et	al.,	1997;	Zauli	et	al.,	1994).	
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Two	studies	showed	that	CD34+	CD4high	and	CD4low/-	populations	include	clonogenic	progenitors	 and	 Louache	 et	al	 furthermore	 demonstrated	 that	 CD34+	 CD4+	HSPCs	are	enriched	for	long-term	culture-initiating	cells	(Louache	et	al.,	1994;	Zauli	et	al.,	1994).	Another	 study	extended	 these	 results	using	human	 fetal	 liver	 to	 show	 that	CD34+CD4+	cells	are	able	to	engraft	in	an	immunodeficient	mouse,	unlike	CD34+CD4-	cells	(Muench	et	al.,	1997).			The	viruses	tested	here	are	shown	to	target	a	CD4high	subset	of	HSPCs,	which	does	correlate	with	other	studies	of	the	CD4	requirement	of	different	HIV	envelope	proteins.	 	 	CCR5-tropic	envelopes	that	infect	macrophages	have	been	shown	to	use	low	 levels	 of	 CD4	 for	 entry	 (Joseph	 et	 al.,	 2014;	 Walter	 et	 al.,	 2005),	 and	 the	envelopes	here	that	infect	HSPCs	are	likely	using	relatively	low	levels	of	CD4	as	well.	The	subset	defined	here	as	CD4highis	the	subset	with	relatively	high	CD4	expression	within	 HSPCs,	 which	 have	 previously	 been	 shown	 to	 be	 much	 lower	 in	 CD4	expression	overall	than	CD4+	T	cells	(Louache	et	al.,	1994;	Zauli	et	al.,	1994).		Thus,	envelopes	 that	 have	 the	 highest	 infection	 in	 HSPCs	 do	 require	 CD4	 for	 entry,	 but	may	have	a	preference	for	cells	with	low	CD4	expression	similar	to	macrophages.	Preferential	 infection	 of	 the	 CD4high	 subset	 provides	 an	 explanation	 for	another	 study	 that	 failed	 to	 detect	 provirus	 in	 HSPCs	 from	 infected	 people.	 This	small	study	of	8	donors	(3	initiating	therapy	during	chronic	infection	and	5	initiating	therapy	during	acute	infection)	that	failed	to	detect	HIV	in	CD34+	bone	marrow	cells	isolated	a	CD4low/-	population	(Josefsson	et	al.,	2012).		Thus,	we	support	a	model	in	which	CD4high	HSPCs	 are	 an	HIV	 reservoir.	 	However,	more	 studies	 are	 needed	 to	determine	the	half-life	of	these	cells.	
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Another	study	that	failed	to	detect	HIV	in	HSPCs	in	11	long-term	infected	people	with	undetectable	plasma	virus	may	not	have	utilized	a	sufficiently	sensitive	assay	to	detect	provirus	in	HSPC	(Durand	et	al.,	2012).	Here,	we	optimized	PCR	conditions	to	single	copy	sensitivity	prior	to	screening	cells	to	use	donor-optimized	primer	sets,	and	we	analyzed	a	larger	cohort	to	better	define	these	persistently	infected	cells.	The	possibility	that	our	results	are	confounded	by	T	cell	contamination	is	highly	unlikely	based	on	a	statistical	analysis	that	takes	into	account	the	level	of	T	cell	contamination	and	the	frequency	of	provirus	in	contaminating	populations	(Table	3-2	and	Table	3-3).	Additionally,	our	study	included	two	donors	with	non-subtype	B	proviruses,	extending	the	conclusion	that	HIVs	of	other	clades	infect	HSPCs	and	persist	in	these	cells	in	people	on	prolonged	therapy.	In	particular,	the	detection	of	subtype	C	HIV	in	highly	purified	preparations	of	HSPCs	establishes	that	these	cells	have	significance	for	 the	most	 common	 type	 of	 HIV	 found	worldwide.	 These	 results	 are	 consistent	with	a	prior	study	reporting	the	presence	of	subtype	C	virus	in	CD34+	HSPCs	from	viremic	 people	 in	 Africa	 (Redd	 et	 al.,	 2007)	 and	 another	 study	 showing	 active	infection	 of	 CD133+	HSPCs	 in	vitro	 by	 subtype	 C	 and	 subtype	D	 Env	 pseudotyped	virus	(Carter	et	al.,	2011).		Interestingly,	 we	 also	 observed	 that	 a	 significant	 subset	 of	 persistent	provirus,	all	 from	CCR5	antagonist-naïve	donors,	appears	to	be	relatively	resistant	to	 receptor	 blockade	 with	 maraviroc.	 While	 this	 result	 is	 consistent	 with	 other	studies	 that	 have	 found	primary	 isolates	 that	 demonstrate	 resistance	 to	 this	 drug	
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(Delobel	et	al.,	2013;	Seclen	et	al.,	2010;	Soulie	et	al.,	2008),	its	clinical	significance	is	unknown.		Overall,	 our	 results	 have	 important	 implications	 for	 understanding	 HSPC	infection	 as	 a	 potential	 barrier	 to	 a	 cure	 for	HIV	 globally.	Moreover,	 the	 evidence	presented	 here	 suggesting	 HIV	 persists	 in	 non-stem	 cell	 progenitors	 supports	 a	recently	revised	model	of	normal	hematopoiesis	that	is	deserving	of	further	study.		
Methods	
Clinical	Samples	We	recruited	HIV-positive	donors	currently	receiving	antiretroviral	therapy	from	the	University	of	Michigan	HIV-AIDS	Treatment	Program	and	the	Henry	Ford	Health	System.	Informed	consent	was	obtained	according	to	a	protocol	approved	by	the	University	of	Michigan	Institutional	Review	Board	and	Henry	Ford	Institutional	Review	Board.	At	the	time	of	sample	acquisition,	all	donors	were	>18	years	old,	had	normal	white	blood	cell	counts,	and	had	plasma	viral	loads	of	<48	copies/mL	for	at	least	6	months.	20	ml	of	bone	marrow	was	aspirated	from	the	posterior	iliac	crest,	collected	 in	 preservative-free	 heparin,	 and	 processed	 immediately.	 100	 mL	 of	peripheral	blood	was	collected	in	K2-EDTA	vacutainer	tubes	and	also	processed	the	same	 day.	 Bone	 marrow	 mononuclear	 cells	 (BMMCs)	 and	 peripheral	 blood	mononuclear	 cells	 (PBMCs)	 were	 isolated	 by	 Ficoll-Paque	 density	 separation	 (GE	Healthcare).	Sort	1	and	Sort	2	HSPCs	were	then	isolated	from	BMMCs	as	 indicated	below.	A	 fraction	 of	 each	 clinical	 sample	 was	 stained	 with	 R-phycoerythrin–
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conjugated	 anti-CD133	 (Miltenyi	 Biotec),	 fluorescein	 isothiocyanate-conjugated	anti-CD34	(eBioscience),	allophycocyanin-conjugated	anti-CD3	(eBioscience),	and	7-aminoactinomycin	 D	 (7-AAD).	 Samples	 were	 analyzed	 on	 a	 BD	 FACSCanto.	 The	donors	who	provided	samples	analyzed	in	this	study	are	a	subset	of	a	larger	cohort	and	 four	 of	 the	 donors	 included	 provided	 multiple	 donations	 with	 3-9	 months	between	donations.	Only	samples	that	were	at	least	80%	CD133+	for	Sort	1	or	80%	CD34+	for	Sort	2,	with	<	2.0	%	CD3+	contamination	were	considered	in	our	analysis	(Table	3-2).		
Cell	Isolation	and	Culture	Whole	 umbilical	 cord	 blood	 (CB)	 was	 obtained	 from	 the	 New	 York	 Blood	Center	and	whole	bone	marrow	was	obtained	commercially	(AllCells	Ltd.);	healthy	cord	blood	mononuclear	cells	(CBMCs)	or	BMMCs	were	purified	by	Ficoll-Hypaque	centrifugation	 and	 then	 used	 either	 fresh	 or	 after	 storage	 in	 liquid	 nitrogen.	Adherent	 cells	were	depleted	 from	CMBCs	or	BMMCs	by	 incubation	 in	 serum-free	StemSpan	 media	 (StemCell	 Technologies)	 for	 1-2	 hours	 at	 37°C,	 and	 then	 Sort	 1	(CD133+	 cells)	 was	 isolated	 by	magnetic	 separation	 with	 a	 CD133	MicroBead	 Kit	(Miltenyi	 Biotec)	 according	 to	 the	 manufacturer’s	 protocol	 with	 the	 following	modifications.	To	achieve	higher	yields	of	CD133+	cells,	1.5x	the	recommended	ratio	of	CD133	MicroBeads	to	cells	was	used	for	donations	451000,	453000,	and	454304.	CBMCs	or	BMMCs	that	flowed	through	the	first	column	(CD133-depleted)	were	used	for	 isolating	 the	 Sort	 2	 (CD133low/-CD34+)	 fraction	 by	 magnetic	 sorting	 with	 the	EasySep	 Human	 CD34	 Positive	 Selection	 Kit	 (StemCell	 Technologies).	 For	 both	
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CD133	and	CD34	magnetic	isolations,	cells	were	sequentially	sorted	on	2	columns	to	increase	purity.	For	one	cord	blood	donor	included	in	Figure	3-11,	lineage-positive	cells	 were	 depleted	 using	 the	 EasySep	 Lineage	 Depletion	 Kit	 (StemCell	Technologies)	before	proceeding	to	the	CD133	magnetic	sort.	For	 in	vitro	 infection	studies,	 isolated	HSPCs	were	cultured	 in	STIF	medium	(StemSpan	 medium	 supplemented	 with	 100	 ng/ml	 stem	 cell	 factor,	 100	 ng/ml	thrombopoietin,	 100	 ng/ml	 Flt3	 ligand	 [all	 from	 StemCell	 Technologies],	 and	 100	ng/ml	 insulin-like	 growth	 factor	 binding	protein	 2	 [R&D	Systems]).	 Viruses	 for	 in	
vitro	 studies	 were	 generated	 in	 293T	 producer	 cells	 propagated	 in	 Dulbecco’s	Modified	Eagle	Medium	(DMEM)	supplemented	with	10%	fetal	bovine	serum	(Gibco	Invitrogen)	 and	 1	 U/ml	 penicillin,	 1	 μg/ml	 streptomycin,	 292	 μg/ml	 glutamine	(Gibco	 Invitrogen).	 For	 tropism	 phenotype	 assays,	 Molt4-CCR5	 cells	 were	propagated	in	RPMI-1640	supplemented	with	10%	fetal	bovine	serum	(R10,	Gibco	Invitrogen),	 1	U/ml	penicillin,	 1	μg/ml	 streptomycin,	 292	μg/ml	 glutamine	 (Gibco	Invitrogen),	 and	 1	mg/mL	 G418	 (Invitrogen)	 and	 NIH-3T3	 CD4+CCR5+	 cells	 were	propagated	in	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	supplemented	with	10%	fetal	bovine	serum	(Gibco	Invitrogen),	1	U/ml	penicillin,	1	μg/ml	streptomycin,	and	292	μg/ml	glutamine	(Gibco	Invitrogen),	and	3	μg/ml	puromycin	(Invitrogen).	Methylcellulose	 colony-forming	 assays	 were	 conducted	 according	 to	 the	manufacturer’s	 protocol	 (Methocult	 H4034,	 StemCell	 Technologies).	 HSPCs	 were	plated	at	limiting	dilution	in	cytokine-containing	methylcellulose	medium.	Colonies	were	 manually	 scored	 on	 days	 14-16	 in	 a	 blinded	 fashion	 by	 three	 investigators	based	 on	 morphology	 using	 an	 inverted	 brightfield	 microscope	 at	 40X	 or	 100X	
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magnification.		
Isolation	of	CD4-negative	Progeny		All	solutions	for	thawing,	staining	and	cell	sorting	contained	20	U/ml	DNAseI	(Roche)	 to	 reduce	 cell	 clumping.	 Thawed	 donor	 PBMC	 were	 depleted	 of	 CD4	expressing	 cells	 with	 CD4	 MicroBeads	 (Miltenyi	 Biotec)	 according	 to	 the	manufacturer’s	protocol	modified	for	a	bead:cell	ratio	of	1.5:1	and	passed	over	two	sequential	 LS	magnetic	 columns.	 Flowthrough	 fractions	were	 pooled	 and	 blocked	with	 FACS	 buffer	 containing	 40	 ng/ml	 4',6-diamidino-2-phenylindole	dihydrochloride	(DAPI,	Fisher	Scientific)	for	20	min	on	ice	before	staining	on	ice	for	the	 following:	 	 	 CD3	 (APC-H7-conjugated,	 BD	 Bioscience),	 CD4	 (AlexaFluor488	conjugated,	 eBioscience),	CD8	 (PE	 conjugated,	BioLegend),	CD19	 (APC	conjugated,	BD	 Bioscience),	 and	 CD56	 (PE-Cy7	 conjugated,	 eBioscience).	 Cells	 were	 washed	once	 with	 FACS	 buffer,	 resuspended	 at	 5x106	 c/ml	 in	 phosphate	 buffered	 saline	without	calcium	or	magnesium	(PBS),	then	filtered	through	a	30	µm	pre-separation	filter	(Miltenyi	Biotec)	prior	to	sorting	on	a	MoFlo	Astrios	flow	cytometer.	Sort	gates	were	 set	 on	 compensated,	 doublet	 excluded	 DAPI-negative	 viable	 cells	 for	monocytes	(forward	scatter	high,	CD3-CD4dim),	CD8	T	cells	(CD3+CD4-CD8+),	B	cells	(CD3-CD4-CD19+CD56-),	 and	 NK	 cells	 (CD3-CD4-CD19-CD56+).	 	 Sorted	 populations	were	analyzed	for	purity	by	setting	gates	based	on	isotype	controls.	To	 assess	 the	 frequency	 of	 amplicons	 in	 CD4+	 T	 cells,	magnetically	 labeled	CD4+	cells	from	above	were	cultured	overnight	in	R10	medium	at	a	density	of	up	to	15x106	 cells	 per	 6-well	 plate.	 	 Adherence-depleted	 CD4+	 T	 cells	were	 stained	 the	
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next	day	with	DAPI,	AlexaFluor488	conjugated	anti-CD4,	APC-conjugated	anti-CD14	(BioLegend),	and	APC-H7-conjugated	anti-CD3	as	described	above	and	acquired	on	a	BD	FACSCanto	cytometer.			
Polymerase	Chain	Reaction	(PCR)	Cells	were	lysed	in	MagNA	Pure	DNA	Lysis/Binding	Buffer	(Roche),	and	DNA	extracted	 using	 a	MagNA	 Pure	 Compact	 System	 (Roche).	 A	 2-step	 PCR	 assay	was	validated	 for	 single	 copy	 sensitivity	 on	ACH-2	 cell	 DNA.	 For	 each	 donor,	 first	 and	second	 round	 primers	 used	 for	 HSPC	 DNA	 analysis	 were	 first	 verified	 by	amplification	of	proviral	sequences	from	PBMC	DNA.	Primer	sequences	are	listed	in	
Table	3-5.	First	round	primer	pairs	for	Env	included	5036d	plus	LTR-pA-R,	5956d-f	plus	LTR-pA-R,	or	envC2F2	plus	envC4R1,	along	with	primers	to	amplify	a	region	of	Gag	 (U5-577.9662-f	 plus	 tagD4.6b-p24R1d	 plus	 or	 minus	 long1316-D4.6b	depending	on	 the	patient	 sequence).	 Second	 round	primer	pairs	 included	5956d-f	plus	 LTR-pA-R,	 envC2F2	 plus	 envC4R1,	 or	 env1in5	 (Brennan	 et	 al.,	 2009)	 plus	env1in3	(Brennan	et	al.,	2009)	for	env	amplification.			For	gag	amplification,	second	round	primers	were	626s	(Hasegawa	et	al.,	1985)	plus	D4.6b	(Buszczak	et	al.,	2014).		 In	 the	 first	 round,	5	μL	of	 template	DNA	at	 limiting	dilution	 (maximum	0.1	copies/uL	 with	 ≤25%	 of	 reactions	 expected	 positive)	 was	 amplified	 in	 50-μL	reactions	containing	10	μl	of	5X	Phusion	HF	Buffer	(ThermoFisher),	1U	of	Phusion	Hot	Start	II	High	Fidelity	DNA	Polymerase	(ThermoFisher),	500nM	of	each	primer,	and	200	μM	deoxyribonucleotide	triphosphates	(dNTPs).	ACH-2	(Clouse	et	al.,	1989)	cell	DNA	was	diluted	in	DNA	from	uninfected	PBMCs	to	serve	as	a	positive	control	
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(10	HIV	genomes	per	μl)	or	 control	 for	 sensitivity	 (0.2	HIV	genomes	per	μl).	DNA	from	 uninfected	 PBMCs	 was	 used	 as	 a	 negative	 control.	 Thermocycling	 was	conducted	using	a	BioRad	C1000	 thermocycler	with	conditions	 indicated	 in	Table	
3-5.	 In	 the	second	round,	1	μl	of	 the	 first	 round	reaction	was	amplified	 in	50-μl	reactions	containing	10	μl	of	5X	Phusion	HF	Buffer,	1U	of	Phusion	Hot	Start	II	High	Fidelity	 DNA	 Polymerase	 (ThermoFisher),	 500nM	 of	 each	 primer	 and	 200	 μM	dNTPs.	 Thermocycling	 was	 conducted	 using	 a	 BioRad	 C1000	 thermocycler	 with	cycling	conditions	as	in	Table	3-5.		
DNA	Sequencing	Analysis	and	Cloning	PCR	 reactions	 were	 run	 on	 1.5%	 agarose	 Tris-acetate-EDTA	 gels	 with	 1X	GelRed	 (Biotium),	 the	 amplicons	 excised,	 extracted	 using	 QIAquick	 Gel	 Extraction	Kit	 (Qiagen),	 and	 then	 sequenced	 by	 Sanger	 dideoxy	 sequencing.	 Consensus	sequences	 were	 generated	 using	 SeqMan	 (DNAStar)	 and	 contaminants	 were	excluded	 after	 comparison	 to	 all	 previously	 generated	 donor	 sequences	 and	 lab	strains	 in	 MEGA6	 (Tamura	 et	 al.,	 2013).	 For	 co-receptor	 usage	 prediction,	 V3	nucleotide	 sequences	 were	 submitted	 to	 an	 online	 genotypic	 algorithm,	Geno2pheno	 (http://coreceptor.geno2pheno.org/index.php),	 with	 a	 false	 positive	rate	cutoff	of	10%	(Lengauer	et	al.,	2007;	Poveda	et	al.,	2012).	Molecular	 phylogenetic	 analysis	 was	 performed	 by	 maximum	 likelihood	method	using	MEGA7	(Kumar	et	al.,	2016).	The	evolutionary	history	was	inferred	by	using	the	Maximum	Likelihood	method	based	on	the	Hasegawa-Kishino-Yano	model	
	 111	
(Hasegawa	 et	 al.,	 1985).	 The	 tree	 with	 the	 highest	 log	 likelihood	 (-2805.4022)	 is	shown.	 Initial	 tree(s)	 for	 the	 heuristic	 search	 were	 obtained	 automatically	 by	applying	 Neighbor-Join	 and	 BioNJ	 algorithms	 to	 a	 matrix	 of	 pairwise	 distances	estimated	 using	 the	 Maximum	 Composite	 Likelihood	 (MCL)	 approach,	 and	 then	selecting	 the	 topology	 with	 superior	 log	 likelihood	 value.	 A	 discrete	 Gamma	distribution	 was	 used	 to	 model	 evolutionary	 rate	 differences	 among	 sites	 (5	categories	 (+G,	 parameter	 =	 0.8699)).	 Codon	 positions	 included	 were	1st+2nd+3rd+Noncoding.	 All	 positions	 with	 less	 than	 95%	 site	 coverage	 were	eliminated.	 That	 is,	 fewer	 than	 5%	 alignment	 gaps,	 missing	 data,	 and	 ambiguous	bases	were	allowed	at	any	position.		 Full-length	 env	 amplicons	 were	 PCR	 purified	 using	 the	 QIAquick	 PCR	Purification	 Kit	 (Qiagen).	 	 3'	 adenine	 overhangs	 were	 added	 using	 Taq	 DNA	Polymerase	 (New	 England	 BioLabs).	 	 Each	 sequence	 was	 cloned	 with	 the	pcDNA3.1/V5-His-TOPO	 TA	 Expression	 Kit	 (Invitrogen)	 according	 to	manufacturer’s	 protocol	 and	 then	 transformed	 into	 Stbl2	 (Invitrogen)	 competent	bacteria.	
	
Viral	Preparation	and	Transductions	Infectious	supernatants	were	prepared	by	 transfection	of	proviral	plasmids	into	 293T	 cells	 using	 polyethylenimine.	 Plasmids	with	 NL4-3	 and	 YU2	 full-length	constructs	 were	 transfected	 to	 produce	 wildtype	 virus.	 HIV-7SF-GFP	 was	 co-transfected	with	the	helper	plasmid	pCMV-HIV-1	(Gasmi	et	al.,	1999)	and	a	plasmid	encoding	 either	 the	 vesicular	 stomatitis	 virus	 glycoprotein	 (VSVG)	 or	 an	 HIV	
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Envelope	 protein.	 Viruses	 pseudotyped	 with	 HIV	 envelope	 proteins	 were	 used	either	 un-concentrated	 or	 concentrated	 using	 high-molecular-weight	 polyethylene	glycol	precipitation	as	described	previously	(Carter	et	al.,	2011;	Kohno	et	al.,	2002).	Cells	 were	 infected	 by	 spin	 inoculation	 at	 1,048.6xg	 for	 2	 hours	 at	 room	temperature.	 For	 infection	 with	 entry	 inhibitors,	 cells	 were	 incubated	 with	AMD3100	 (10	mg/mL)	 and/or	maraviroc	 (20	 μM)	 for	 at	 least	 15	minutes	 before	infection,	during	spin	inoculation,	and	in	cell	culture	for	2-3	days	following	infection.	
	
Flow	cytometry	and	antibodies.		Antibodies	 to	 the	 following	 proteins	were	 used	 for	 flow	 cytometry:	 CD133	(phycoerythrin	 [PE]	 conjugated;	 Miltenyi	 Biotec),	 CD34	 (conjugated	 with	fluorescein	 isothiocyanate	 [FITC],	 allophycocyanin	 [APC],	 PE-Cy7;	 Miltenyi	 Biotec	and	 eBioscience),	 CD4	 (OKT4	 clone	 unconjugated,	 Brilliant	 Violet	 605	 conjugated;	BD	Biosciences),	CD45RA	(APC	conjugated;	eBioscience),	CD38	(PE-Cy7	conjugated;	eBioscience),	 CD10	 (Biotin	 conjugated;	 eBioscience),	HIV-1	Gag	 (clone	KC57,	 FITC	conjugated;	 Beckman	 Coulter),	 and	 Human	 Hematopoietic	 Lineage	 Cocktail	 (FITC	conjugated;	eBioscience).	The	secondary	reagents	used	were	streptavidin	(Brilliant	Violet	 421	 conjugated;	 BD	 Biosciences)	 and	 anti-mouse	 IgG2b	 (Alexa	 Fluor	 647	conjugated;	Invitrogen).	Cells	were	stained	with	7-aminoactinomycin	D	(7-AAD)	to	exclude	 dead	 cells.	 Samples	 were	 analyzed	 using	 a	 BD	 FacsCanto	 cytometer.	 Cell	sorting	 was	 performed	 using	 a	 MoFlo	 XDP	 (Beckman	 Coulter),	 MoFlo	 Astrios	(Beckman	Coulter),	or	FACSAria	(BD	Biosciences)	flow	cytometer.	For	 staining	 surface	 proteins,	 cells	 were	 first	 incubated	 in	 fluorescence-activated	
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cell	sorting	(FACS)	buffer	(phosphate-buffered	saline	[PBS]	with	2%	FBS,	1%	human	serum,	 2	mM	 HEPES,	 and	 0.025%	 sodium	 azide)	 on	 ice	 for	 20	min	 with	 directly	conjugated	 antibodies	 or	 primary	 antibodies.	 Cells	 were	 then	 washed	 and,	 if	necessary,	stained	with	a	secondary	antibody	for	an	additional	20	min	on	ice.	They	were	 then	washed	 and	 fixed	 in	 PBS	with	 2%	 paraformaldehyde.	 For	 intracellular	staining	of	HIV	Gag,	cells	were	first	fixed	and	then	permeabilized	with	0.1%	Triton	X-100	in	PBS	for	5	min	at	room	temperature.	Cells	were	then	washed	and	incubated	with	an	antibody	against	Gag	for	30	min	on	ice.	
	
Isolation	of	murine	cells	Bone	marrow	cells	were	 isolated	 and	harvested	 as	described	 (Signer	 et	 al.,	2014).	 For	 flow	 cytometric	 analysis	 and	 isolation	 of	 specific	 hematopoietic	progenitors,	cells	were	incubated	with	combinations	of	antibodies	to	the	following	cell-surface	markers	 conjugated	 to	 FITC,	 PE,	 PerCP-Cy5.5,	 APC,	 PE-Cy7,	 or	 biotin:	CD3ε	(17A2),	CD4	(GK1.5),	CD5	(53-7.3),	CD8α	(53-6.7),	CD11b	(M1/70),	CD16/32	(FcΥRII/III;	 93),	 CD34	 (RAM34),	 CD43	 (1B11),	 CD44	 (IM7),	 CD45R	 (B220;	 RA3-6B2),	 CD48	 (HM48-1),	 CD117	 (c-kit;	 2B8),	 CD127	 (IL7Rα;	 A7R34),	 CD150	 (TC15-12F12.2),	 Ter119	 (TER-119),	 Sca1	 (D7,	 E13-161.7),	 Gr-1	 (RB6-8C5),	 and	 IgM	(II/41).	For	 isolation	of	CD150+CD48-Lineage-Sca-1+c-kit+	 (CD150+CD48-LSK)	HSCs	and	CD150-CD48-LSK	MPPs,	 Lineage	markers	 included	CD3,	 CD5,	 CD8,	B220,	Gr-1,	and	 Ter119.	 For	 isolation	 of	 CD34+CD16/32lowCD127-Sca-1-LK	 CMPs	 and	CD34+CD16/32highCD127-Sca-1-LK	 GMPs,	 these	 Lineage	 markers	 were	supplemented	with	antibodies	against	CD4	and	CD11b.	Biotinylated	antibodies	were	
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visualized	 by	 incubation	 with	 PE-Cy7	 conjugated	 streptavidin.	 All	 reagents	 were	acquired	from	BD	Biosciences,	eBiosciences,	or	BioLegend.	All	incubations	were	for	approximately	30	minutes	on	ice.	HSCs,	MPPs,	CMPs,	and	GMPs,	were	pre-enriched	by	selecting	c-kit+	cells	using	paramagnetic	microbeads	and	an	autoMACS	magnetic	separator	(Miltenyi).	Other	sorted	populations	included	Gr-1+	cells,	IgM-CD43+B220+	pro-B	 cells,	 IgM-CD43-B220+	 pre-B	 cells,	 and	 unfractionated	 bone	 marrow	 cells.	Non-viable	cells	were	excluded	from	sorts	and	analyses	using	DAPI.	Cell	sorting	was	performed	 on	 a	 FACSAria	 (BD	 Biosciences).	 All	 fractions	 were	 double	 sorted	 to	ensure	high	purity.	
	
Gene	Expression	Analysis	of	Isolated	HSPC	Subsets	Gene	 expression	 in	 human	 bone	 marrow	 HSPC	 and	 differentiated	 subsets	assessed	by	microarray	analysis	was	extracted	from	a	published	data	set	(Rapin	et	al.,	 2014)	 accessed	 via	 the	NCBI	 Gene	 Expression	Omnibus	 database	 (GSE42519).	For	RNAseq	analysis	of	murine	hematopoietic	cells,	RNA	was	extracted	from	3x104	double-sorted	cells	from	each	cell	population	using	the	mirVana	miRNA	isolation	kit	(Thermo	 Scientific).	 Total	 RNA	 was	 quantified	 using	 a	 Bioanalyzer	 (Agilent).	 To	assess	mRNA	content,	we	performed	RNAseq	on	the	total	RNA	extracted	from	each	cell	 population,	 adding	 equal	 amounts	 of	 92	 spiked-in	RNA	 standards	 to	 each	 cell	population.	Since	the	amount	of	spiked-in	RNA	standards	added	to	each	sample	was	known,	 the	 relationship	 between	 RPKM	 values	 and	 the	 number	 of	 transcripts	 for	each	spiked-in	RNA	could	be	determined	by	regression	analysis	(Loven	et	al.,	2012).	RNAseq	reads	were	aligned	using	Bowtie	software	(Langmead	et	al.,	2009)	to	NCBI	
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build	37	(mm9)	of	 the	mouse	genome	with	the	settings:	 -e	70	-k	1	-m	2	-	n	2.	The	RPKM	 for	 each	 RefSeq	 gene	 and	 synthetic	 spike-in	 RNA	 was	 calculated	 using	RPKM_count.py	 (v2.3.5)	 counting	 only	 exonic	 reads	 (-e	 option).	 Loess	 regression	from	R	 affy	 package	was	 used	 to	 renormalize	 the	RPKM	values	 by	 using	 only	 the	spike-in	RNA	to	fit	the	loess	with	default	parameters.	Only	the	spike-in	RNAs	whose	abundance	could	be	robustly	quantified	(RPKM	values	≥	1)	were	used	 in	 the	 loess	normalization.		
Statistical	Analysis	T	 cell	 contamination	 analysis	 was	 performed	 for	 HSPC	 and	 non-CD4+	progeny	sequences	as	described	as	 in	McNamara	et	al	(McNamara	et	al.,	2013).	All	other	statistical	tests	were	performed	using	Excel	or	GraphPad	Prism	5.0a.		 	
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Amplicon	 PCR	Round	 Primer	 Orientation	
HXB2	
Location	 Sequence	
env	 1st	 5036d	 Forward	 5036-5059	 5′-GGAYTATGGAAAACAGATGGCAGG-3’	
env	 1st	or	2nd	 LTR-pA-R	 Reverse	 9625-9600	 5′-AGGCAAGCTTTATTGAGGCTTAAGC	A-3’	
env	 1st	or	2nd	 5956d-f	 Forward	 5956-5983	 5′-CTTAGGCATYTCCTATGGCAGGAAG	AAG-3’	
env	 1st	or	2nd	 envC2F2	 Forward	 6950–6976	 5′-CAGCACAGTACAATGTACACATGGA	AT-3’	
env	 1st	or	2nd	 envC4R1	 Reverse	 7540-7520	 5′-ATGGGAGGGGCATACATTGC	T-3′	
env	 2nd	 env1in5	 Forward	 7060-7081	 5′-ACAATGCTAAAACCATAATA	GT-3′	
env	 2nd	 env1in3	 Reverse	 7530-7511	 5′-CATACATTGCTTTTCCTACT-3′	
gag	 1st	 U5-577.9662-f	 Forward	 577-603	 5’-GACTCTGGTAACTAGAGATC	CCTCA	GA-3’	
gag	 1st	 long1316-D4.6b	 Reverse	 1322-1316	 5’-atcttgcggcgctctgtgTGGGGTGGCTCCTTCTG-3’	
gag	 1st	 tagD4.6b-p24R1d	 Reverse	 1500-1480	 5’-atcttgcggcgctctgtgTGCTATGTCACTTCCCCTTGG-3’	
gag	 2nd	 626s	 Forward	 626-651	 5’-TCTCTAGCAGTGGCGCCCGAACAGGG-3’	


















































































































































































Appendix A  
Provirus in Bone Marrow Hematopoietic 
Progenitor Cells Matches Residual Plasma Virus 























the	University	of	Michigan	Institutional	Review	Board	and	Henry	Ford	Institutional	Review	Board.	At	the	time	of	sample	acquisition,	all	donors	were	>18	years	old,	had	normal	white	blood	cell	counts,	and	had	plasma	viral	loads	of	<48	copies/mL	for	at	least	6	months.	20	ml	of	bone	marrow	was	aspirated	from	the	posterior	iliac	crest,	collected	 in	 preservative-free	 heparin,	 and	 processed	 immediately.	 100	 mL	 of	peripheral	blood	was	collected	in	K2-EDTA	vacutainer	tubes	and	also	processed	the	same	 day.	 Bone	 marrow	 mononuclear	 cells	 (BMMCs)	 and	 peripheral	 blood	mononuclear	 cells	 (PBMCs)	 were	 isolated	 by	 Ficoll-Paque	 density	 separation	 (GE	Healthcare).	Sort	1	and	Sort	2	HSPCs	were	then	isolated	from	BMMCs	as	 indicated	below.		Diluted	plasma	from	the	Ficoll-Paque	separation	of	the	peripheral	blood	was	pelleted	by	ultracentrifugation	at	112,398xg	for	1.5-3	hours	at	4°C	and	resuspended	in	1	mL	Trizol	Reagent	(ThermoFisher)	and	stored	at	-80°C.	A	 fraction	 of	 each	 clinical	 sample	 was	 stained	 with	 R-phycoerythrin–conjugated	 anti-CD133	 (Miltenyi	 Biotec),	 fluorescein	 isothiocyanate-conjugated	anti-CD34	(eBioscience),	allophycocyanin-conjugated	anti-CD3	(eBioscience),	and	7-aminoactinomycin	 D	 (7-AAD).	 Samples	 were	 analyzed	 on	 a	 BD	 FACSCanto.	 The	donors	who	provided	samples	analyzed	in	this	study	are	a	subset	of	a	larger	cohort	and	 four	 of	 the	 donors	 included	 provided	 multiple	 donations	 with	 3-9	 months	between	donations.	Only	samples	that	were	at	least	80%	CD133+	for	Sort	1	or	80%	CD34+	for	Sort	2,	with	<	2.0	%	CD3+	contamination	were	considered	in	our	analysis	(Table	3-2).		
Cell	Isolation	
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Adherent	cells	were	depleted	from	CMBCs	or	BMMCs	by	incubation	in	serum-free	StemSpan	media	(StemCell	Technologies)	for	1-2	hours	at	37°C,	and	then	Sort	1	(CD133+	 cells)	 was	 isolated	 by	magnetic	 separation	 with	 a	 CD133	MicroBead	 Kit	(Miltenyi	 Biotec)	 according	 to	 the	 manufacturer’s	 protocol	 with	 the	 following	modifications.	To	achieve	higher	yields	of	CD133+	cells,	1.5x	the	recommended	ratio	of	CD133	MicroBeads	to	cells	was	used	for	donations	451000,	453000,	and	454304.	CBMCs	or	BMMCs	that	flowed	through	the	first	column	(CD133-depleted)	were	used	for	 isolating	 the	 Sort	 2	 (CD133low/-CD34+)	 fraction	 by	 magnetic	 sorting	 with	 the	EasySep	 Human	 CD34	 Positive	 Selection	 Kit	 (StemCell	 Technologies).	 For	 both	CD133	and	CD34	magnetic	isolations,	cells	were	sequentially	sorted	on	2	columns	to	increase	purity.		




Cells	were	lysed	in	MagNA	Pure	DNA	Lysis/Binding	Buffer	(Roche),	and	DNA	extracted	 using	 a	MagNA	 Pure	 Compact	 System	 (Roche).	 A	 2-step	 PCR	 assay	was	validated	 for	 single	 copy	 sensitivity	 on	ACH-2	 cell	 DNA.	 For	 each	 donor,	 first	 and	second	 round	 primers	 used	 for	 HSPC	 DNA	 analysis	 were	 first	 verified	 by	amplification	of	proviral	sequences	from	PBMC	DNA.	Primer	sequences	are	listed	in	
Table	3-5.	First	round	primer	pairs	for	Env	included	5036d	plus	LTR-pA-R,	5956d-f	plus	LTR-pA-R,	or	envC2F2	plus	envC4R1,	along	with	primers	to	amplify	a	region	of	Gag	 (U5-577.9662-f	 plus	 tagD4.6b-p24R1d	 plus	 or	 minus	 long1316-D4.6b	depending	on	 the	patient	 sequence).	 Second	 round	primer	pairs	 included	5956d-f	plus	 LTR-pA-R,	 envC2F2	 plus	 envC4R1,	 or	 env1in5	 (Brennan	 et	 al.,	 2009)	 plus	env1in3	(Brennan	et	al.,	2009)	for	env	amplification.			For	gag	amplification,	second	round	primers	were	626s	(Hasegawa	et	al.,	1985)	plus	D4.6b	(Buszczak	et	al.,	2014).		 In	 the	 first	 round,	5	μL	of	 template	DNA	at	 limiting	dilution	 (maximum	0.1	copies/uL	 with	 ≤25%	 of	 reactions	 expected	 positive)	 was	 amplified	 in	 50-μL	reactions	containing	10	μl	of	5X	Phusion	HF	Buffer	(ThermoFisher),	1U	of	Phusion	Hot	Start	II	High	Fidelity	DNA	Polymerase	(ThermoFisher),	500nM	of	each	primer,	and	200	μM	deoxyribonucleotide	triphosphates	(dNTPs).	ACH-2	(Clouse	et	al.,	1989)	cell	DNA	was	diluted	in	DNA	from	uninfected	PBMCs	to	serve	as	a	positive	control	(10	HIV	genomes	per	μl)	or	 control	 for	 sensitivity	 (0.2	HIV	genomes	per	μl).	DNA	from	 uninfected	 PBMCs	 was	 used	 as	 a	 negative	 control.	 Thermocycling	 was	conducted	using	a	BioRad	C1000	 thermocycler	with	conditions	 indicated	 in	Table	
3-5.	 In	 the	second	round,	1	μl	of	 the	 first	 round	reaction	was	amplified	 in	50-μl	
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reactions	containing	10	μl	of	5X	Phusion	HF	Buffer,	1U	of	Phusion	Hot	Start	II	High	Fidelity	 DNA	 Polymerase	 (ThermoFisher),	 500nM	 of	 each	 primer	 and	 200	 μM	dNTPs.	 Thermocycling	 was	 conducted	 using	 a	 BioRad	 C1000	 thermocycler	 with	cycling	conditions	as	in	Table	3-5.		
DNA	Sequencing	Analysis	and	Cloning	PCR	 reactions	 were	 run	 on	 1.5%	 agarose	 Tris-acetate-EDTA	 gels	 with	 1X	GelRed	 (Biotium),	 the	 amplicons	 excised,	 extracted	 using	 QIAquick	 Gel	 Extraction	Kit	 (Qiagen),	 and	 then	 sequenced	 by	 Sanger	 dideoxy	 sequencing.	 Consensus	sequences	 were	 generated	 using	 SeqMan	 (DNAStar)	 and	 contaminants	 were	excluded	 after	 comparison	 to	 all	 previously	 generated	 donor	 sequences	 and	 lab	strains	in	MEGA6	(Tamura	et	al.,	2013).	Molecular	 phylogenetic	 analysis	 was	 performed	 by	 maximum	 likelihood	method	using	MEGA7	(Kumar	et	al.,	2016).	The	evolutionary	history	was	inferred	by	using	the	Maximum	Likelihood	method	based	on	the	Hasegawa-Kishino-Yano	model	(Hasegawa	 et	 al.,	 1985).	 The	 tree	 with	 the	 highest	 log	 likelihood	 (-2805.4022)	 is	shown.	 Initial	 tree(s)	 for	 the	 heuristic	 search	 were	 obtained	 automatically	 by	applying	 Neighbor-Join	 and	 BioNJ	 algorithms	 to	 a	 matrix	 of	 pairwise	 distances	estimated	 using	 the	 Maximum	 Composite	 Likelihood	 (MCL)	 approach,	 and	 then	selecting	 the	 topology	 with	 superior	 log	 likelihood	 value.	 A	 discrete	 Gamma	distribution	 was	 used	 to	 model	 evolutionary	 rate	 differences	 among	 sites	 (5	categories	 (+G,	 parameter	 =	 0.8699)).	 Codon	 positions	 included	 were	1st+2nd+3rd+Noncoding.	 All	 positions	 with	 less	 than	 95%	 site	 coverage	 were	
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eliminated.	 That	 is,	 fewer	 than	 5%	 alignment	 gaps,	 missing	 data,	 and	 ambiguous	bases	were	allowed	at	any	position.	
	































Plasma	 PBMC	 Plasma	 PBMC	414000	 1	 2	 2	 1	 0	 7	421000	 0	 0	 0	 1	 1	 4	434423	 1	 17	 8	 1	 5	 5	
435412406	 0	 0	 0	 1	1	1	
0	3	0	
3	18	2	436000	 0	 0	 0	 1	 22	 2	
*First	3	digits	is	donation	number;	subsequent	groups	of	3	digits	are	ID	of	previous	donation(s)	from	the	same	individual,	if	any.			 	
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Figure	A-1.	Plasma	virus	sequences	are	often	clonal	and	are	identical	to	HSPC	
amplicons	in	several	donors.			
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Maximum	likelihood	phylogenetic	trees	from	three	representative	donors	show	genetic	relationships	of	gag	and	env	sequences	from	bone	marrow,	peripheral	blood,	and	plasma	virus.	Highlighted	areas	indicate	groups	of	identical	amplicons.	Scale	indicates	nucleotide	substitutions	per	site.8		 	
																																																								8	Figure	created	by	Val	Terry.	
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